PROCESSO PARA O DESENVOLVIMENTO DE UM IMUNOENSAIO DE MICROARRANJO DE PEPTÍDEOS PARA AVALIAÇÃO SOROLÓGICA DO STATUS VACINAL PARA FEBRE AMARELA, PLACA DE MICROARRANJO DE PEPTÍDEOS, IMUNOENSAIO, USO DE PLACA DE MICROARRANJO DE PEPTÍDEOS, E, KIT PARA AVALIAÇÃO SOROLÓGICA DO STATUS VACINAL PARA FEBRE AMARELA

A peptide microarray immunoassay using fluorescence intensity analysis effectively differentiates vaccinated and unvaccinated individuals, addressing the limitations of existing methods and optimizing vaccine distribution.

BR102025008725A2Pending Publication Date: 2026-11-10FUNDACAO OSWALDO CRUZ (FIOCRUZ)
0 Cites 0 Cited by

Patent Information

Application Number
BR102025008725
Authority / Receiving Office
BR · BR
Patent Type
Applications
Current Assignee / Owner
Filing Date
2025-05-02
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Current methods for assessing yellow fever vaccination status, such as the Plaque Reduction Neutralization Test (PRNT), are laborious, require specialized infrastructure, and lack standardization, hindering the identification of individuals who need primary vaccination or booster doses, especially in routine clinical laboratories.

Method used

Development of a peptide microarray immunoassay using a library of 149 peptides to identify linear B-cell epitopes, optimized through fluorescence intensity analysis, allowing differentiation between vaccinated and unvaccinated individuals.

Benefits of technology

The peptide microarray assay provides a practical and effective method for evaluating vaccination status, supporting the identification of vaccine failures and optimizing vaccine distribution protocols, with improved reproducibility and cost-effectiveness.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader
Need to check novelty before this filing date? Find Prior Art

Description

1 / 69 PROCESS FOR THE DEVELOPMENT OF A PEPTIDE MICROARRAY IMMUNOASSAY FOR SEROLOGICAL EVALUATION OF YELLOW FEVER VACCINATION STATUS, PEPTIDE MICROARRAY PLATE, IMMUNOASSAY, USE OF PEPTIDE MICROARRAY PLATE, AND KIT FOR SEROLOGICAL EVALUATION OF YELLOW FEVER VACCINATION STATUS FIELD OF THE INVENTION

[0001] The present invention relates to a process for developing a peptide microarray immunoassay for serological assessment of vaccination status for Yellow Fever. The present invention also relates to a peptide microarray plate for serological assessment of vaccination status for Yellow Fever. The present invention also relates to an immunoassay for serological assessment of vaccination status for Yellow Fever. The present invention also relates to the use of the peptide microarray plate for serological assessment of vaccination status for Yellow Fever. The present invention also relates to a kit for serological assessment of vaccination status for Yellow Fever, which allows differentiation between primary vaccinated individuals (PV) and unvaccinated individuals (NV). BACKGROUND OF THE INVENTION General Aspects of Yellow Fever

[0002] Yellow Fever (YF) is an acute, non-contagious, febrile infectious disease subject to mandatory and immediate notification, whose etiological agent is the Yellow Fever virus (YFV) (BRAZIL, 2017a; GOULD et al., 2017). YFV belongs to the genus Flavivirus (family Flaviviridae) and Petition 870260057968, dated 06 / 15 / 2026, page 7 / 78 2 / 69 consists of an enveloped spherical viral particle 50 nanometers in diameter (DOUAM and PLOSS, 2018; KLITTING et al., 2018). Its genetic material consists of a positive-sense ribonucleic acid (RNA) molecule containing 10,862 nucleotides, including a single open reading frame (ORF) accompanied by non-coding regions at the 5' and 3' ends, necessary for viral translation and replication (MCELROY et al., 2006; DOUAM and PLOSS, 2018; KLITTING et al., 2018). The VFA genome encodes a polyprotein with 3,411 amino acids (aa) that, after co- and post-translational modifications by viral and host proteases, gives rise to three structural proteins: capsid (C), membrane [immature (prM) and mature (M) forms], and envelope (E), in addition to seven nonstructural (NS) proteins: NS1, NS2A-2B, NS3, NS4A-4B, and NS5 (MCELROY et al., 2006; PATKAR and KUHN, 2008; DOUAM and PLOSS, 2018; KLITTING et al., 2018).

[0003] Yellow fever is an arboviral disease, meaning it is transmitted to humans by arthropods of the genera Sabethes spp, Haemagogus spp, and Aedes spp. (VASCONCELOS, 2002; QUARESMA et al., 2013; BRASIL, 2017b; GOULD et al., 2017; DOMINGO et al., 2018). Yellow fever occurs in three epidemiological modalities, including sylvatic, intermediate, and urban cycles. Regardless of the cycle, the disease is the same in all clinical forms; however, there is variability in the manifestation of symptoms (VASCONCELOS, 2002; VASCONCELOS, 2003; QUARESMA et al., 2013; JOHANSSON et al., 2014; BRASIL, 2017a; DOMINGO et al., 2018). The asymptomatic and / or mild form occurs in approximately 90% of cases (fever, myalgia, nausea, vomiting and arthralgia) (VASCONCELOS, 2003; Petition 870260057968, dated 06 / 15 / 2026, p. 8 / 78 3 / 69 (BRAZIL, 2017b; WAGGONER et al., 2018; BRAZIL, 2019). Between 10 and 25% of patients develop severe forms, presenting with jaundice, hemorrhage, hepatorenal failure, cardiac and pancreatic damage, sepsis, associated with high lethality (VASCONCELOS, 2003; BRAZIL, 2017b). Since there are many asymptomatic cases, there is a large underreporting of cases of the disease (VASCONCELOS, 2003; JOHANSSON et al., 2014; REZENDE et al., 2020).

[0004] This disease is of epidemiological importance since factors such as increased population susceptibility to infection, deforestation, migratory movements, and climate change have been identified as responsible for the increase in the number of FA cases in recent years (ORTIZ-MARTÍNEZ et al., 2017; WORLD HEALTH ORGANIZATION, 2018). It is estimated that between 80,000 and 200,000 cases of FA occur annually, of which 30,000 to 60,000 are fatal, corresponding to a mortality rate of 20 to 60% (DOUAM and PLOSS, 2018).

[0005] The disease is considered a significant public health problem in Africa and Latin America, being endemic in 27 and 13 countries, respectively, which are at imminent potential for transmission (WORLD HEALTH ORGANIZATION, 2018). Given the fluctuating epidemiology of yellow fever, characterized by intense and periodic outbreaks, as well as the resurgence of disease vectors and the risk of international spread of the etiological agent, this disease becomes an emerging global threat that requires new strategic thinking (DOMINGO et al., 2018; WORLD HEALTH ORGANIZATION, 2018; DAVIS and BARRETT, 2020). Petition 870260057968, dated 06 / 15 / 2026, page 9 / 78 4 / 69

[0006] Since there is no specific treatment for yellow fever infection, the 17D and 17DD yellow fever vaccines, currently recommended by the World Health Organization (WHO), have been considered the main prophylactic interventions for controlling the disease (FERREIRA et al., 2018; KLITTING et al., 2018; WORLD HEALTH ORGANIZATION, 2018). The expansion of viral circulation areas and the intensification of the flow of people reveal high demands for doses of the yellow fever vaccine, which have not been met due to a significant shortage of vaccine doses (POSSAS et al., 2018). This scenario is characterized by the recurrent depletion of vaccine stocks as a consequence of the current limited vaccine production capacity (MARTINS et al., 2018).

[0007] Available yellow fever vaccines have high safety and efficacy (DAVIS and BARRETT, 2020). The immune response triggered by the vaccine is characterized by the participation of various cell types and their mediators (AKONDY et al., 2009; CAMPI-AZEVEDO et al., 2012; HOU et al., 2017; FERREIRA et al., 2018), as well as neutralizing antibodies, experimentally correlated with long-lasting resistance to wild virus infection (CAMACHO et al., 2004; FERREIRA et al., 2018; COSTA-ROCHA et al., 2019).

[0008] There is a wide spectrum of protective correlates, both related to humoral and cellular responses, available and used to assess the vaccination status of vaccinated individuals (REINHARDT et al., 1998; GOTUZZO et al., 2013; CAMPI-AZEVEDO et al., 2016; WIETEN et al., 2016; COSTA-PEREIRA et al., 2018; COSTA-ROCHA et al., 2019). However, methodological and operational limitations exist for the identification of Petition 870260057968, dated 06 / 15 / 2026, page 10 / 78 5 / 69 individuals with negative serological status for yellow fever represent a major challenge for the optimization and rational use of the yellow fever vaccine. Such limitations hinder the selection of individuals who should be included in the population contingent vulnerable to infection by the wild yellow fever virus and receive primary vaccination or booster doses.

[0009] The classic Plaque Reduction Neutralization Test (PRNT) is used as a reference method for evaluating natural infection, vaccine efficacy, and the duration of post-vaccination immunity by verifying neutralizing antibody titers (SIMÕES et al., 2012). The test is based on the principle that infectious viral particles are neutralized by specific antibodies present in the serum of individuals and thus lose the ability to infect permissive cells. Specifically, the test consists of verifying the ability of dilutions of a serum sample to prevent the formation of plaque lysis in monolayers of cells susceptible to infection (SIMÕES et al., 2012).Among the limitations inherent to PRNT, the following stand out: its laborious nature as a functional assay employing long-term cultures; the need for periodic validations of cut-off points; and difficulties in obtaining interlaboratory standardization due to the need to use reference serum for the release of results in international units. Furthermore, there is no international consensus on the use of the PRNT50%, PRNT80%, or PRNT90% plate reduction criteria (JONKER et al., 2013). In order to overcome these limitations, methodological changes have already been presented to optimize the PRNT assay, such as the conversion of conventional PRNT in 6-well plates to 96-well plates. Petition 870260057968, dated 06 / 15 / 2026, page 11 / 78 6 / 69 (microPRNT). In addition, the use of automated reading systems employing image software associated with new staining systems has been implemented. Complementarily, the establishment of seroneutralization platforms using microassays with a detection system employing yellow fever monoclonal antibody (microPRN) has allowed for a reduction in assay time, thus optimizing the release of results.

[0010] Although the PRNT test is the most suitable for measuring seroprotection following vaccination, it is a heterogeneous method that requires specific infrastructure, standardized controls, and qualified operators for its execution, revealing limitations of the technique that can hinder the reproducibility and comparison of results and diagnosis in outbreak situations (COLLABORATIVE GROUP FOR STUDIES WITH YELLOW FEVER VACCINE et al., 2014; DOMINGO et al., 2018).

[0011] Due to the lack of practical methods for assessing yellow fever vaccination status, the development of new, easy-to-perform laboratory methods represents an important strategy for enabling the assessment of serological status for this disease in routine clinical laboratories. As already mentioned, although the PRNT is the international reference method for defining serological vaccination status, even with the modifications already made for its optimization, this test remains restricted to reference laboratories. Therefore, the search for new methods capable of practically defining yellow fever vaccination status in routine clinical laboratories represents a challenge for the scientific community. Petition 870260057968, dated 06 / 15 / 2026, page 12 / 78 7 / 69

[0012] A promising strategy for assessing vaccination status against yellow fever is the use of microarrays of peptides from the yellow fever vaccine virus 17DD. Patent searches identified documents relating to the use of microarrays for assessing vaccination status against some infections, such as document US10,261,081, which discloses a microarray assay for evaluating the efficacy of influenza vaccine using hemagglutinin (HA) protein as a capture antigen. Document WO2015 / 031904 discloses a microarray containing 4,528 P. falciparum proteins used to identify individuals protected against malaria, either for vaccination campaigns or in clinical vaccination studies. Document WO2021 / 117038, in turn, discloses a microarray assay containing whole influenza viruses or peptides of influenza H1N1, H3N2 and B to assess vaccine efficacy or the need for an individual to be vaccinated. The ML documentWumkes (2017) uses a microarray assay containing hemagglutinins from influenza viruses H1, H2, H3, H5, H7, and H9 to evaluate the efficacy of the influenza vaccine in patients undergoing chemotherapy. Finally, the MC Moreno-Bondi (2006) document describes a microarray assay that can be used to evaluate vaccination efficacy using antigens of tetanus toxin, CRM toxin of diphtheria, enterotoxin B of Staphylococcus, and hepatitis B virus. However, none of the documents found use microarrays to assess yellow fever vaccination status.

[0013] In this context, in search of a practical and effective method to identify the population contingent vulnerable to infection by the wild yellow fever virus, a process was developed in the present invention to Petition 870260057968, dated 06 / 15 / 2026, page 13 / 78 8 / 69 performing a microarray immunoassay of yellow fever vaccine virus 17DD (YFV) peptides based on the identification of a library of potentially immunogenic peptides containing linear B-cell epitopes.

[0014] Certainly, knowledge of antigenic sequences derived from proteins of the yellow fever vaccine virus 17DD recognized by immunoglobulins from unvaccinated and vaccinated individuals is an important tool for monitoring immunity induced by the yellow fever vaccine. Furthermore, it can support more refined studies for the development of a laboratory test with practical application for evaluating yellow fever vaccination status.

[0015] In this context, the present application postulated that 149 peptides of the microarray in question (VFA Peptide Microarray) are sufficient to segregate vaccinated individuals from unvaccinated individuals. Complementarily, the present application comparatively evaluated the performance of the VFA Peptide Microarray using samples from a biorepository from a controlled study and a real-world biorepository. This new study identified a set of 136 peptides of the microarray capable of segregating vaccinated individuals from unvaccinated individuals. Together, both studies aimed to: optimize the performance of the VFA Peptide Microarray, calculate costs, and evaluate the reproducibility, concordance, and interchangeability of using serum and plasma samples in the VFA Peptide Microarray assays.

[0016] The use of this peptide microarray immunoassay for the evaluation of 17DD yellow fever vaccination status will support analyses Petition 870260057968, dated 06 / 15 / 2026, page 14 / 78 9 / 69 more complex and sophisticated aspects related to the immunoglobulin recognition repertoire of vaccinated individuals. In addition to the immunoassay, a strategy for analyzing the results was also developed in the present invention.

[0017] Taken together, given the current epidemiological scenario of the rapid expansion of yellow fever, the precise identification of primary (absence of seroconversion after primary vaccination) and secondary (reduction of neutralizing antibodies below protective levels over time) vaccine failures will directly impact the reshaping of the current demand for vaccine doses, assisting in the definition and updating of primary vaccination and periodic revaccination protocols, a topic of high interest to the WHO and the Brazilian National Immunization Program (PNI). SUMMARY OF THE INVENTION

[0018] In one aspect, the present invention relates to a process for developing a peptide microarray immunoassay for serological assessment of yellow fever vaccination status, consisting of the following steps: a. Selection of epitopes based on literature and prediction of linear B-cell epitopes using at least one of three different predictors; b. Selection of epitopes from step (a) with the highest antigenic potential using secondary antibodies labeled with fluorescent molecules to select peptides reactive to sera from unvaccinated (NV) and primary vaccination (PV) samples; c. Analysis using a computer program; Petition 870260057968, dated 06 / 15 / 2026, page 15 / 78 10 / 69 d. Identification of the most accurate fluorescence intensity (FI) thresholds and evaluation of their performance using the specific target peptides identified at each fluorescence intensity threshold, as well as performance indices expressed as a percentage for the correct classification of individual NV and PV samples; e. Grouping of selective peptides from PV samples into matrices of different IF thresholds and identification of valid IF threshold zones with constant performance indices; f. Combination of peptide sets capable of correctly classifying PV samples from Biorepository #1, from a controlled study, and Biorepository #2, from a real-world study, without redundancy (#239 + #144 - #45 redundant peptides = #338 peptides); g. selection of the highest IF thresholds and exclusion of reactive peptides with NV samples from both biorepositories.

[0019] In a further aspect, the predictors of step (a) must be linear B-cell epitope predictors. In yet another aspect, the program of step (c) must be a fluorescence intensity analysis program. In yet another aspect, the peptide microarray comprises sequences from SEQ ID NO: 1 to 136.

[0020] The aforementioned process, through a specific selection of peptides, allows differentiation between individuals with a positive / persistent vaccination status for Yellow Fever and unvaccinated individuals.

[0021] In another aspect, the present invention relates to a peptide microarray plate for serological assessment of vaccination status for Petition 870260057968, dated 06 / 15 / 2026, page 16 / 78 11 / 69 Yellow fever, comprising at least two of the peptide sequences represented among SEQ ID NO: 1 to 136. In a further aspect, the peptide microarray plate is preferably an optical microscopy slide. In yet another aspect, the addition of peptides to the microarray plate is preferably performed by laser printing with solid-phase peptide synthesis.

[0022] In another aspect, the present invention relates to an immunoassay for serological evaluation of vaccination status for Yellow Fever, comprising the following steps: a) Wash and block the peptide microarray plate as defined previously; b) Pre-label the peptide microarray plate from step (a) with anti-IgG secondary antibody; c) Quantify the fluorescence intensity signal; d) Wash the peptide microarray plate from step (c) and incubate with the test samples; (e) Wash the peptide microarray plate from step (d) and incubate with anti-IgG secondary antibody; f) Wash the peptide microarray plate from step (e) and incubate with anti-HA control antibody; g) Wash the peptide microarray plate from step (f); eh) Quantify the fluorescence intensity signal.

[0023] In a further aspect, the immunoassay test sample is preferably serum or plasma. In another further aspect, the secondary antibody emits fluorescence in the red light spectrum, Petition 870260057968, dated 06 / 15 / 2026, page 17 / 78 12 / 69 preferably at 650nm and the control antibody to emit fluorescence in the green light spectrum preferably at 550nm.

[0024] In another aspect, the invention relates to the peptide microarray plate and the use of said peptide microarray plate to differentiate PV from NV individuals for Yellow Fever. In a further aspect, the microarray comprises at least two of the sequences, preferably from SEQ ID No. 1 to SEQ ID No. 49.

[0025] In another aspect, the invention relates to the kit for serological evaluation of vaccination status for Yellow Fever comprising at least: (a) a peptide microarray plate as defined above; (b) secondary anti-IgG antibody conjugated with fluorescent molecules; and (c) anti-HA control antibody conjugated with fluorescent molecules. BRIEF DESCRIPTION OF THE FIGURES

[0026] The object of the invention, together with its additional advantages, could be better understood by reference to the accompanying figures and the following descriptions:

[0027] Figure 1 demonstrates the selection process of the 726 yellow fever 17DD vaccine virus peptides conducted using in silico approaches and based on three primary steps: (1) prospecting for linear B-cell epitopes of the yellow fever 17DD vaccine virus; (2) selection of yellow fever 17DD vaccine virus peptides; and (3) preparation of the VFA-PEPperCHIP® peptide microarray immunoassay. Petition 870260057968, dated 06 / 15 / 2026, page 18 / 78 13 / 69

[0028] Figure 2 shows the schematic model of the VFA Peptide Microarray device (slide), the incubation apparatus (PEPperCHIP®), with capacity for 3 slides, each containing 5 microarrays, and the schematic model of the immunoassay. (A) The VFA Peptide Microarray devices consist of 25 x 75 mm optical microscope slides containing five identical copies of the 726 epitopes of the yellow fever vaccine virus 17DD polyprotein printed in duplicate (gray circle). Each microarray is framed by spacers (white circle), as well as 44 spots containing poliomyelitis peptide (red circle) and 46 spots containing influenza virus hemagglutinin peptide (green circle), configuring the internal assay controls. (B) PEPperCHIP® incubation apparatus that supports the use of 3 VFA Peptide Microarray slides. The apparatus consists of an incubation plate, compatible silicone seal, mounting bracket and lid.Once the system is assembled, wells are created for the addition of individual samples and reagents. (C) Schematic model of the VFA Peptide Microarray Standard Operating Procedure which includes three main steps: 1) Pre-labeling with the anti-IgG-DyLight®650 secondary antibody; 2) Incubation with the samples, followed by the anti-IgG-DyLight®650 secondary antibody; and 3) Labeling with the anti-HA-DyLight®550 control antibody. (Adapted).

[0029] Figure 3 presents the schematic model for calculating the resulting fluorescence intensity (FI) of the peptides. (A) Each 25 x 75 mm light microscopy slide of the VFA Peptide Microarray contains five identical copies of the 726 epitopes of the yellow fever vaccine virus 17DD polyprotein printed in duplicate (gray circle), spacers (white circle), as well as 44 spots containing poliomyelitis peptide. Petition 870260057968, dated 06 / 15 / 2026, page 19 / 78 (A) Schematic representation of the pre-labeling step with the anti-IgG secondary antibody and the incubation step with the test sample and secondary antibody. (B) Elements used to calculate the resultant of each spot and the final fluorescence intensity result of each peptide. Initially, the median values ​​of the fluorescence intensity are obtained for each spot: including the raw data value 1 (I + II) and the background value 1 (II), referring to the signals from the pre-labeling step with the anti-IgG-DyLight®650 secondary antibody; and the raw data value 2 (I + II) and the background value 2 (II), referring to the signals from the incubation step with the test sample and the anti-IgG-DyLight®650 secondary antibody.The foreground 1 and foreground 2 values ​​for each spot, corresponding to the signals from the pre-labeling and incubation steps with the test sample, respectively, are calculated by the difference between the raw data values ​​and the background values. The resulting fluorescence intensity for each spot is calculated by the difference between the foreground 2 and foreground 1 values. Then, by calculating the average of the resulting values ​​from the duplicates of each spot, the final fluorescence intensity value for each peptide is obtained.

[0030] Figure 4 shows the performance of the VFA Peptide Microarray model proposed by the researchers of the present invention for evaluating the 17DD yellow fever vaccine serological status. (A) Performance of the VFA Peptide Microarray using samples from Biorepository #1 (controlled study), composed of paired samples of Unvaccinated individuals - NV (green circle, n=15) and Primary Vaccination individuals - PV (red circle, n=15). (B) Performance of the Peptide Microarray Petition 870260057968, dated 06 / 15 / 2026, page 20 / 78 15 / 69 VFA employing samples from Biorepository #2 (real-life study), composed of paired NV (blue circle, n=9) and PV (yellow circle, n=9) samples. Performance results are presented in scatter plots of the sum (Σ) reactivity of the set of #149 peptides using combined analysis of different fluorescence intensity thresholds [IF>(0) / (5) / (20)]. ROC curves illustrate the overall accuracy performance index (area under the ROC curve - AUC).

[0031] Figure 5 presents an exploratory analysis of peptide recognition by samples from Biorepository #1 and Biorepository #2 using the VFA Peptide Microarray. The graphs show the panoramic profile of recognition of the 726 peptides distributed along the yellow fever vaccine virus 17DD polyprotein by serum samples from (A) Biorepository #1 [NV (green circle) and PV (red circle)] and from (B) Biorepository #2 [NV (blue circle) and PV (yellow circle)] using the VFA Peptide Microarray. The average fluorescence intensity (FI) was calculated for each peptide considering the values ​​resulting from the duplicates. The sets of peptides recognized differentially in Biorepository #1 (controlled study) and Biorepository #2 (real-life study) are identified by elliptical shapes.The peptide clusters with preferential recognition profiles for PV samples in both biorepositories are identified by rectangular shapes.

[0032] Figure 6 shows analysis of the VFA Peptide Microarray using robust statistical performance analysis tools. (A) Performance of the VFA Peptide Microarray using samples from Biorepository #1 (controlled study), composed of paired NV samples. Petition 870260057968, dated 06 / 15 / 2026, page 21 / 78 (A) Performance of the VFA Peptide Microarray using samples from Biorepository #1 (controlled study), composed of paired samples NV (green circle, n=15) and PV (red circle, n=15) and samples from Biorepository #2 (real-life study), composed of paired samples NV (blue circle, n=9) and PV (yellow circle, n=9). Peptide #640 was used as an example of selectivity for PV in both biorepositories. (B) Performance of the VFA Peptide Microarray using samples from Biorepository #1 (controlled study), composed of paired samples NV (green circle, n=15) and PV (red circle, n=15) and samples from Biorepository #2 (real-life study), composed of paired samples NV (blue circle, n=9) and PV (yellow circle, n=9). Peptide #137 was used as an example of a peptide that exhibits different performance between the two biorepositories. ROC curves illustrate the performance index (AUC, Sen, and Esp). TG-ROC curves define the valid zones of IF thresholds (gray band) in which the performance indices remain constant.

[0033] Figure 7 shows the selection of peptides and respective IF thresholds [Σ>(0) / (5) / (10) / (20) / (30) / (40) / (50) / (100) / (200) / (500) / (1000) / (2000)] for the evaluation of 17DD yellow fever vaccine serological status. (A) Selection of PV-specific peptides for the correct classification of serum samples from Biorepository #1 and Biorepository #2, with their respective IF thresholds. (B) Performance of the VFA Peptide Microarray using samples from Biorepository #1 (controlled study), composed of paired NV (green circle, n=15) and PV (red circle, n=15) samples, and Biorepository #2 (real-life study), composed of paired NV (blue circle, n=9) and PV (yellow circle, n=9) samples. The performance results are presented in scatter plots of the sum of reactivity of the #239 array. Petition 870260057968, dated 06 / 15 / 2026, page 22 / 78 17 / 69 specific PV peptides from Biorepository #1 and #144 peptides for Biorepository #2 using combined analysis of different fluorescence intensity thresholds. [Σ>(0) / (5) / (10) / (20) / (30) / (40) / (50) / (100) / (200) / (500) / (1000) / (2000)]. ROC curves illustrate the overall accuracy performance index (area under the ROC curve - AUC).

[0034] In order to identify the set of peptides capable of correctly classifying PV samples, two analysis strategies were performed with the aim of optimizing the performance of the VFA Peptide Microarray. The results are presented in Figures 8 and 9.

[0035] Figure 8 presents strategies for optimizing the performance of the VFA Peptide Microarray using the set of common peptides. (A) Schematic model of the Venn Diagram employing the set of #239 PV-specific peptides from Biorepository #1 (controlled study) and the set of #144 PV-specific peptides from Biorepository #2 (real-life study) for the selection of the set of common peptides. #45 common peptides, reactive to PV serum samples from both biorepositories, were identified as capable of correctly classifying PV samples. However, only 8 peptides were at the same IF threshold for correct classification of PV samples in both biorepositories (5 peptides IF>0 and 3 peptides IF>5).The use of the VFA Peptide Microarray with 8 peptides did not show good performance using PV samples from Biorepository #1 (Sen=53% and Esp=100%), Biorepository #2 (Sen=44% and Esp=100%) or both biorepositories (Sen=50% and Esp=100%). (Data not shown). (B) Performance of the Microarray. Petition 870260057968, dated 06 / 15 / 2026, page 23 / 78 18 / 69 VFA peptides using samples from Biorepository #1 (controlled study), composed of paired NV (green circle, n=15) and PV (red circle, n=15) samples and Biorepository #2 (real-life study), composed of paired NV (blue circle, n=9) and PV (yellow circle, n=9) samples. (C) Overall performance of the sample set of Biorepository #1 and Biorepository #2. The performance results are presented in scatter plots of the sum (Σ) of reactivity of the set of common #45 (lower IF threshold) and common #45 (higher IF threshold) specific to PV from Biorepository #1 and Biorepository #2.

[0036] Figure 9 describes strategies for optimizing the performance of the VFA Peptide Microarray using the union of specific peptides from PV samples from Biorepository #1 and Biorepository #2, without redundancy (without considering the 45 common peptides) and excluding peptides reactive with NV samples. (A) Schematic model, capable of correctly classifying PV samples, employing the union of the set of #239 specific PV peptides from Biorepository #1 (controlled study) and the set of #144 specific PV peptides from Biorepository #2 (real-life study), without redundancy and excluding peptides reactive with NV samples. Subsequently, peptides that showed reactivity when using samples from NV individuals from Biorepository #1 and Biorepository #2 were excluded. The exclusion was performed using Microsoft Excel (2019) by searching for reactive peptides in PV in both biorepositories.PV-reactive peptides in only one of the biorepositories were disqualified, resulting in #99 PV-reactive peptides using the lowest IF threshold and #136 PV-reactive peptides using the highest IF threshold. Petition 870260057968, dated 06 / 15 / 2026, page 24 / 78 19 / 69 (B) Performance of the VFA Peptide Microarray using samples from Biorepository #1 (controlled study), composed of paired NV (green circle, n=15) and PV (red circle, n=15) samples and Biorepository #2 (real-life study), composed of paired NV (blue circle, n=9) and PV (yellow circle, n=9) samples. (C) Overall performance of the sample set from Biorepository #1 and Biorepository #2. The performance results are presented in scatter plots of the sum (Σ) reactivity of the PV-specific #99 union (lower IF threshold) and #136 union (higher IF threshold) sets from Biorepository #1 and Biorepository #2.

[0037] Figure 10 shows strategies aimed at optimizing the costs of the VFA Peptide Microarray employing minimum peptide selection with lower and higher IF thresholds. (A) Schematic model of the diagram used for minimum peptide selection while maintaining sensitivity and specificity. (B) Performance of the VFA Peptide Microarray using samples from Biorepository #1 (controlled study), composed of paired NV (green circle, n=15) and PV (red circle, n=15) samples, and Biorepository #2 (real-life study), composed of paired NV (blue circle, n=9) and PV (yellow circle, n=9) samples. (C) Overall performance of the sample set. Biorepository #1 and Biorepository #2. The performance results are presented in scatter plots of the sum (Σ) reactivity of the set of #47 minimal selection peptides (lowest IF threshold) and #49 minimal selection peptides (highest IF threshold) specific to PV from Biorepository #1 and Biorepository #2.

[0038] Figure 11 shows the performance and costs of Microarrays Petition 870260057968, dated 06 / 15 / 2026, page 25 / 78 20 / 69 of optimized VFA Peptides. (A) Comparison of the overall performance of the sample set from Biorepository #1 (controlled study) and Biorepository #2 (real-life study). Results are presented in scatter plots of the sum (Σ) reactivity of the set of common #45 (highest IF threshold), #99 union (lowest IF threshold) and #136 union (highest IF threshold), #47 minimum selection (lowest IF threshold) and #49 minimum selection (highest IF threshold). (B) Estimated costs of the original (*) and optimized VFA Peptide Microarrays, according to quotations obtained from the microarray slide manufacturer. NA = not applicable. The lines marked in bold represent the optimized VFA Peptide Microarrays that presented the best indices and lowest costs.

[0039] Figure 12 depicts the comparative localization of peptides along the VFA-17DD polyprotein in the original VFA Peptide Microarrays and optimized peptide microarrays. (A) Localization of #726 peptides in the yellow fever vaccine precursor polyprotein 17DD and the #45 common (highest IF threshold), #99 Union (lowest IF threshold) and #136 Union (highest IF threshold), #47 minimum selection (lowest IF threshold) and #49 minimum selection (highest IF threshold) clusters of the VFA Peptide Microarrays. Legend: C - Capsid. (B) Heatmap and (C) graphical representation of the percentage of peptides present in each region of the VFA 17DD precursor polyprotein.

[0040] Figure 13 shows the reproducibility of peptide recognition using serum and plasma samples tested on the VFA Peptide Microarray. Representative images of peptide recognition by paired serum and plasma samples from Biorepository #3 (n=6). This biorepository consists of 6 volunteers, 1 male and Petition 870260057968, dated 06 / 15 / 2026, page 26 / 78 21 / 69 women, aged 27 to 82, participated in the study “Heparin removal by ecteolacellulose pre-treatment enables the use of plasma samples for accurate measurement of anti-Yellow fever virus neutralizing antibodies.” This study was conducted in 2013 and 2014 in the cities of Bambuí / Minas Gerais and Vitória / Espírito Santo. Paired samples of peripheral blood were collected with and without heparin anticoagulant (CAMPIAZEVEDO et al., 2017).

[0041] Figure 14 shows the interchangeability of peptide recognition by serum and plasma samples tested on the original and optimized VFA Peptide Microarrays. Comparison of the sum of IF values ​​of peptide reactivity using paired serum (circle) and plasma (square) samples from Biorepository #3 tested on the original and optimized VFA Peptide Microarrays. The results are presented in comparative scatter plots of the sum (Σ) of reactivity of IF values ​​in the original VFA Peptide Microarray of the set of #45 common (highest IF threshold), #99 union (lowest IF threshold) and #136 union (highest IF threshold), #47 minimum selection (lowest IF threshold) and #49 minimum selection (highest IF threshold). DETAILED DESCRIPTION OF THE INVENTION

[0042] Although the present invention may be susceptible to different embodiments, a preferred embodiment is shown in the drawings and in the following detailed discussion, with the understanding that the present description should be considered an exemplification of the principles of the invention and is not intended to limit the present invention to what has been illustrated and described herein. Process for the development of a peptide microarray immunoassay for serological evaluation of vaccine status for Irritable Flea Market fever. Petition 870260057968, dated 06 / 15 / 2026, p. 27 / 78 22 / 69 Yellow

[0043] In one aspect, the present invention relates to a process for developing a peptide microarray immunoassay of the yellow fever vaccine virus 17DD for serological evaluation of yellow fever vaccination status, consisting of the following steps: a. Selection of epitopes based on literature and prediction of linear B-cell epitopes using at least one of three different predictors; b. Selection of epitopes from step (a) with the highest antigenic potential using secondary antibodies labeled with fluorescent molecules to select peptides reactive to sera from unvaccinated (NV) and primary vaccination (PV) samples; c. Analysis using a computer program; d. Identification of the most accurate fluorescence intensity (FI) thresholds and evaluation of their performance using the specific target peptides identified at each fluorescence intensity threshold, as well as performance indices expressed as a percentage for the correct classification of individual NV and PV samples; e. Grouping of selective peptides from PV samples into matrices of different IF thresholds and identification of valid IF threshold zones with constant performance indices; f. Combination of peptide sets capable of correctly classifying PV samples from Biorepository #1, from a controlled study, and Biorepository #2, from a lifetime study. Petition 870260057968, dated 06 / 15 / 2026, page 28 / 78 23 / 69 actual, without redundancy (#239 + #144 - #45 redundant peptides = #338 peptides); g. selection of the highest IF thresholds and exclusion of reactive peptides with NV samples from both biorepositories.

[0044] Figure 1 describes in detail the rationale used for the selection of peptides, detailing the steps of prospecting, selection, and preparation of the microarrays. Slides containing the customized microarrays were used to perform the immunoassay. After incubation with the test samples of interest and additional incubation with secondary antibody labeled with a fluorescent probe, images of the slides were captured using a scanner specifically designed for microarray reading. Finally, the fluorescence intensity of individual reactivity with each peptide was determined by analysis using the PepSlide®Analyzer program.

[0045] Figures 2 and 3 detail the steps for performing the immunoassay as well as the fluorescence intensity components of the reactivity of each peptide. Specifically, Figures 2A and 3A show how the spots are printed onto the microarray slides. Critical steps for optimizing the operational protocol of the VFA Peptide Microarray Immunoassay were established, as follows: adjustment of the sensitivity level of the photomultiplier tube (PMT) for scanning the slides, adequate dilution of the secondary antibody and the test sample.

[0046] Initially, #149 peptides were identified as capable of correctly classifying samples from unvaccinated (NV) individuals from primary (PV) individuals in Biorepository#1 (from a controlled study). In a second approach, this same set of Petition 870260057968, dated 06 / 15 / 2026, page 29 / 78 24 / 69 peptides did not perform as well in segregating NV and PV samples in a Biorepository #2 (from a real-world study).

[0047] Figure 4 demonstrates the performance of the #149 peptides in segregating samples of NV and PV individuals from Biorepository #1 and Biorepository #2. To identify the fluorescence intensity thresholds (FI) with greater accuracy for each of the #726 peptides, for the correct classification of individual NV and PV samples from both biorepositories, TG-ROC curves were used. The performance evaluation using TG-ROC curves allowed the identification of the fluorescence intensity threshold, as well as the performance indices for each of the #726 peptides.

[0048] To improve the selection of peptides with performance for the correct classification of individual NV and PV samples, the selected peptides were grouped into 12 matrices employing different fluorescence intensity (FI) thresholds, considering (FI>0, FI>5, FI>10, FI>20, FI>30, FI>40, FI>50, FI>100, FI>200, FI>500, FI>1000, FI>2000).

[0049] Figures 5 and 6 demonstrate the IF diversity for each of the #726 peptides applied in Biorepositories #1 and #2, as well as the presence of valid zones for IF thresholds. Figure 7A presents the overall profile of the number of reactive peptides in each of the IF matrices.

[0050] Another embodiment of the present invention refers to optimizing the performance of the VFA Peptide Microarray, consisting of the following topics: (1)The peptides capable of correctly classifying PV samples from Biorepository #1 (#239 peptides) and from Petition 870260057968, dated 06 / 15 / 2026, page 30 / 78 25 / 69 Biorepository #2 (#144 peptides) were identified using Venn diagram analysis to exclude NV-selective peptides and common NV and PV peptides; (2)The set of #45 redundant peptides demonstrated good indices for classifying NV and PV samples from both Biorepositories; Figure 8 presents the performance analyses. (3) The set of peptides capable of correctly classifying PV samples from Biorepository #1 and Biorepository #2, without redundancy, totaled #338 peptides (#239 + #144 - #45 redundant peptides = #338 peptides); Figure 9 shows the performance analyses. (4) Next, the selection of reactive peptides with PV samples that employed higher IF thresholds was carried out. After excluding reactive peptides with NV samples from both biorepositories, a total of #136 peptides was obtained; with the approach of employing lower IF thresholds, a total of #99 peptides was obtained; Figure 10 shows the performance analyses. (5) The performance analyses of the set of #136 and #99 reactive peptides with PV samples demonstrated good segregation indices for the samples in both biorepositories; Figure 10 presents the performance analyses. (6) To optimize the costs of the immunoassay, complementary analyses were performed to identify the minimum number of peptides without altering the method's performance, thus totaling #49 peptides applying higher IF thresholds and #47 peptides Petition 870260057968, dated 06 / 15 / 2026, page 31 / 78 26 / 69 applying lower IF thresholds; Figure 11 presents the performance analyses. (7) Based on the final performance results, the set of #49 peptides applying higher IF thresholds could provide excellent cost optimization, since 16 microarrays could be inserted into the slide (solid support) reducing the costs of preparing the immunoassay; Figure 11 shows the performance and estimated costs of the set of peptides applying the immunoassay using the VFA Peptide Microarray. (8)The final selection of #49 peptides presents an intrinsic composition with great immunological support given the location of the peptides along the precursor polyprotein of the yellow fever vaccine 17DD; Figure 12 details the position of the peptides of each set addressed in the previous topics along the polyprotein of the yellow fever vaccine 17DD. (9) The reproducibility, concordance, and interchangeability of the results obtained in the VFA Peptide Microarray were evaluated through a comparative analysis using paired serum and plasma samples from Biorepository #3 on slides containing original VFA Peptide Microarrays. By using the summation results of the IF values, it was observed that the recognition was similar for both biological samples. Figures 13 and 14 show the reproducibility and interchangeability results presented in this step. Table 5 presents the concordance results between paired serum and plasma samples. Petition 870260057968, dated 06 / 15 / 2026, page 32 / 78 27 / 69

[0051] In one embodiment, in the aforementioned process, the predictor in step (a) shall be linear B-cell epitope predictors such as, for example, BCPred, FBCPred, or BepiPred 1.0. In a further embodiment, the program in step (c) shall be a fluorescence intensity analysis program such as, for example, PepSlide® Analyzer. In yet another embodiment, the peptide microarray plate comprises sequences from SEQ ID NO: 1 to 136.

[0052] Figure 2C shows in detail the entire process of performing the immunoassay using the VFA Peptide Microarray. Peptide microarray plate for serological assessment of yellow fever vaccination status.

[0053] In one embodiment, the peptide microarray plate comprises at least two of the peptide sequences represented among SEQ ID NO: 1 to 136.

[0054] In another embodiment, the peptide microarray plate is preferably an optical microscopy slide. In yet another embodiment, the addition of peptides to the microarray plate is preferably performed by laser printing with solid-phase peptide synthesis.

[0055] The aforementioned microarray comprises the set of peptides of SEQ ID NO: 1 to SEQ ID NO: 136, preferably the peptide array from SEQ ID NO: 1 to SEQ ID NO: 49; with peptides of 15 amino acids. In one embodiment, the solid support is a 25x75mm light microscope slide containing the peptide microarrays. In another embodiment, the number of microarrays may be 5 or 16, varying the production cost of performing the immunoassay. Petition 870260057968, dated 06 / 15 / 2026, p. 33 / 78 28 / 69

[0056] Table 1 lists the peptides from SEQ ID No. 1 to SEQ ID No. 136, highlighting the first peptides from SEQ ID No. 1 to SEQ ID No. 49. Table 1 - Listing of peptides from SEQ ID No. 1 to SEQ ID No. 136 SEQ ID NO SEQUENCE NAME SEQUENCE Protein START OF polyprotein END OF POLYPROTEIN 1 Peptide 015 AHLAEENEGDNACKR E 365 379 2 Peptide 020 AKNPVVDGNPTVDIE 240 40 40 3B Peptide 041 ATPPGTSDEFPHSNG NS3 1805 1819 4 Peptide 060 CREQDELIGRVSP NS5 3238 3252 5 Peptide 072 DEINAIFEENEVDIS NS1 851 865 6 Peptide 075 DEVLIEVPFGDSY 667 Peptide 088 DIGESSSSSITEGER NS5 2652 2666 8 Peptide 089 DIHRLEPVKCDTLLC NS5 2637 2651 9 Peptide 094 DKEAIEERVERIKSE NS5 2780 2794 10 Peptide 097 DAAIEERVERIKSE NS5 2780 2794 10 Peptide 097 DAAIEERVERIKSE NS5 3042 11 Peptide 100 DLGKTFSVGTGNCTT pr 139 153 12 Peptide 121 EAHLAEENEGDNACK E 364 378 13 Peptide 128 EENEVDISVVVQDPK NS1 858 872 14 Peptide 100 DLGKTFSVGTGNCTT pr 2921 2935 15 Peptide 158 ETDKGPLDKEAIEER NS5 2773 2787 16 Peptide 177 FHPGAGKTRRFLPQI NS3 1682 1696 17 Peptide 207 GGVWREMHHLVEFEP 125 20186 Peptide GKTLGVNMVRRGVRS C 8 22 19 Peptide 269 IAAVPGKNVVNVQTK NS3 1584 1598 20 Peptide 279 IGESSSSSITEGERT NS5 2653 2667 21 Peptide 321 KERGVNMVRGVER 279776 22Peptide 327 KKWRDVPYLTKRQDK NS5 3341 3355 23 Peptide 328 KLEGRWDGEEEVQLI NS3 1570 1584 Petition 870260057968, dated 06 / 15 / 2026, page 34 / 78 29 / 69 24 Peptide 330 KLIPSWASVKEDLVA NS3 1550 1564 25 Peptide 337 KRQGPKQMLVGGVVL NS2A 1153 1167 26 Peptide 345 KTKQIGNRPGPSRGV C 30 44 27 Peptide 346 KTLGVNMVRRGVRSL C 9 23 28 Peptide 364 LDKEAIEERVERIKS NS5 2779 2793 29 Peptide 366 LEALDYKECEWPLTH NS1 994 1008 30 Peptide 382 LIEGNTSLLWNGPMA NS4B 2463 2477 31 Peptide 395 LRKRQGPKQMLVGGV NS2A 1151 1165 32 Peptide 412 MGERQLQKIERWFVR M 234 248 33 Peptide 468 PSKGWNDWENVPFCS NS5 3206 3220 34 Peptide 469 PSTGEAHLAEENEGD E 360 374 35 Peptide 531 RVTKDTNDNNLYKLH E 548 562 36 Peptide 546 SGDDCVVRPIDDRFG NS5 3171 3185 37 Peptide 547 SGSGGVWREMHHLVE E 504 518 38 Peptide 552 SKGWNDWENVPFCSH NS5 3207 3221 39 Peptide 575 SVEESEMFMPRSIGG NS1 1013 1027 40 Peptide 583 SWPDLDLKPGAAWTV NS4B 2284 2298 41 Peptide 585 SYVTKTSGSAASMVN NS5 2815 2829 42 Peptide 604 TKDTNDNNLYKLHGG E 550 564 43 Peptide 618 TSGSPIVNRNGEVIG NS3 1621 1635 44 Peptide 626 TYKNKVVKVLRPAPG NS5 3079 3093 45 Peptide 645 VGTGNCTTNILEAKY pr 146 160 46 Peptide 646 VGVAQGGVFHTMWHV NS3 15241538 47 Peptide 653 VKVLRPAPGGKAYMD NS5 3085 3099 48 Peptide 692 WDRIEEVTRMAMTDT NS5 2839 2853 49 Peptide 714 YKNKVVKVLRPAPGG NS5 3080 3094 50 Peptide 009 ADLDDEQEILNYMSP NS5 3052 3066 51 Peptide 010 AEAENVIHHQHVQDC NS5 3131 3145 52 Peptide 013 AFQEMENFLGPIAVG NS2B 1375 1389 Petição 870260057968, de 15 / 06 / 2026, pág. 35 / 78 30 / 69 53 Peptide 026 AMDGGGFYADDTAGW NS5 3031 3045 54 Peptide 028 AMRVTKDTNDNNLYK E 546 560 55 Peptide 044 AVPTSWVPQGRTTWS NS5 3292 3306 56 Peptide 050 CDIGESSSSSITEGE NS5 2651 2665 57 Peptide 052 CGLNSVDSLEHEMWR NS1 833 847 58 Peptide 063 CVTVMAPDKPSLDIS E 315 329 59 Peptide 068 DDEVLIEVNPPFGDS E 645 659 60 Peptide 091 DISVVVQDPKNVYQR NS1 863 877 61 Peptide 093 DKCVTVMAPDKPSLD E 313 327 62 Peptide 104 DPPAGTRKIMKVVNR NS5 2872 2886 63 Peptide 135 EGRWDGEEEVQLIAA NS3 1572 1586 64 Peptide 150 EQDKCVTVMAPDKPS E 311 325 65 Peptide 176 FHGVAKNPVVDGNPT NS4B 2396 2410 66 Peptide 187 GAKQENWNTDIKTLK E 431 445 67 Peptide 188 GAMRVTKDTNDNNLY E 545 559 68 Peptide 208 GILVTVNPIASTNDD E 632 646 69 Peptide 213 GKNVVNVQTKPSLFK NS3 1589 1603 70 Peptide 232 GRMGERQLQKIERWF M 232 246 71 Peptide 245 GVAKNPVVDGNPTVD NS4B 2398 2412 72 Peptide 252 GWGNGCGLFGKGSIV E 385 399 73 Peptide 258 HGSDGCWYPMEIRPR NS1 1102 1116 74 Peptide 260 HGVAKNPVVDGNPTV NS4B 2397 2411 75 Peptide 265 HTIGTSVEESEMFMP NS1 1008 1022 76Peptide 267 HVGAKQENWNTDIKT E 429 443 77 Peptide 275 IEGNTSLLWNGPMAV NS4B 2464 2478 78 Peptide 281 IGRGRVSPGNGWMIK NS5 3245 3259 79 Peptide SEMF 283 IRSSV11 1010 1024 80 Peptide 286 IIVGRGDSRLTYQWH E 661 675 81 Peptide 291 ILNYMSPHHKKLAQA NS5 3060 3074 Petition 870260057968, of 15 / 06 / 2026, p. 36 / 78 31 / 69 82 Peptide 296 INDKCPSTGEAHLAE E 355 369 83 Peptide 306 IVGRGDSRLTYQWHK E 662 676 84 Peptide 312 KCVTVMAPDKPSLDI E 314 328 85 Peptide 329 KLGEVSWEEEAEISG NS2B 1409 1423 86 Peptide 332 KNPTDTGHGTVVMQV E 593 607 87 Peptide 349 KVLRPAPGGKAYMDV NS5 3086 3100 88 Peptide 362 LDDEQEILNYMSPHH NS5 3054 3068 89 Peptide 370 LEQDKCVTVMAPDKP E 310 324 90 Peptide 380 LHVGAKQENWNTDIK E 428 442 91 Peptide 381 LIAAVPGKNVVNVQT NS3 1583 1597 92 Peptide 396 LRPAPGGKAYMDVIS NS5 3088 3102 93 Peptide 406 MAEAENVIHHQHVQD NS5 3130 3144 94 Peptide 408 MEVVLRKRQGPKQML NS2A 1147 1161 95 Peptide 409 MEYNCPNLSPREEPD pr 166 180 96 Peptide 418 MTGRMGERQLQKIER M 230 244 97 Peptide 427 NGKKLIPSWASVKED NS3 1547 1561 98 Peptide 430 NKVVKVLRPAPGGKA NS5 3082 3096 99 Peptide 433 NPPFGDSYIIVGRGD E 653 667 100 Peptide 438 NRVWITNNPHMQDKT NS5 3324 3338 101 Peptide 442 PAPGGKAYMDVISRR NS5 3090 3104 102 Peptide 443 PDDIDCWCYGVENVR pr 179 193 103 Peptide 452 PGTSVIIDGNCDGRG NS1 1059 1073 104 Peptide 454 PKFWELVDEERKLHQ NS5 29362950 105 Peptide 471 PTDTGHGTVVMQVKV E 595 609 106 Peptide 473 PTSWVPQGRTTWSIH NS5 3294 3308 107 Peptide 487 QIGNRPGPSRGVQGF C 33 47 108 Peptide 509 RGKSTRSTTDSGKVI NS1 1072 1086 109 Peptide 521 RNGKKLIPSWASVKE NS3 1546 1560 110 Peptide 522 RPAPGGKAYMDVISR NS5 3089 3103 Petition 870260057968, dated 06 / 15 / 2026, page 37 / 78 32 / 69 111 Peptide 530 RVFHGVAKNPVVDGN NS4B 2394 2408 112 Peptide 537 SATLEQDKCVTVMAP E 307 321 113 Peptide 553 SLEHEMWRSRADEIN NS1 840 854 114 Peptide 558 SPRLCTKEEFIAKVR NS5 2897 2911 115 Peptide 563 SSASPWSWPDLDLKP NS4B 2278 2292 116 Peptide 564 SSAVPTSWVPQGRTT NS5 3290 3304 117 Peptide 567 SSSITEGERTVRVLD NS5 2658 2672 118 Peptide 571 STGEAHLAEENEGDN E 361 375 119 Peptide 584 SYIAEMETESWIVDR E 478 492 120 Peptide 591 TDKGPLDKEAIEERV NS5 2774 2788 121 Peptide 596 TGAMRVTKDTNDNNL E 544 558 122 Peptide 597 TGEAHLAEENEGDNA E 362 376 123 Peptide 601 TILMTATPPGTSDEF NS3 1800 1814 124 Peptide 642 VFLHSEEGSRAYRNA NS4A 2136 2150 125 Peptide 656 VLRKRQGPKQMLVGG NS2A 1150 1164 126 Peptide 657 VLRPAPGGKAYMDVI NS5 3087 3101 127 Peptide 662 VPGKNVVNVQTKPSL NS3 1587 1601 128 Peptide 665 VPTSWVPQGRTTWSI NS5 3293 307 129 Peptide 673 VTKDTNDNNLYKLHG E 549 563 130 Peptide 679 VVKVLRPAPGGKAYM NS5 3084 3098 131 Peptide 693 WEEEAEISGSSARYD NS2B 1415 1429 132 Peptide 699 WMTGRMGERQLQKIE M 229 243 133 Peptide709 YCGSYVTKTSGSAAS NS5 2812 2826 134 Peptide 716 YLEEQEQWKTANEAV NS5 2919 2933 135 Peptide 720 YPMEIRPRKTHESHL NS1 1109 1123 136 Peptide 724 YSYYPEDPVKLASIV NS1 810 824 Immunoassay for serological evaluation of vaccination status for Fever Yellow Petition 870260057968, dated 06 / 15 / 2026, p. 38 / 78 33 / 69

[0057] In one embodiment, the immunoassay comprises the following steps: a) Wash and block the peptide microarray plate as defined previously; b) Pre-label the peptide microarray plate from step (a) with anti-IgG secondary antibody; c) Quantify the fluorescence intensity signal; d) Wash the peptide microarray plate from step (c) and incubate with the test samples; (e) Wash the peptide microarray plate from step (d) and incubate with anti-IgG secondary antibody; f) Wash the peptide microarray plate from step (e) and incubate with anti-HA control antibody; g) Wash the peptide microarray plate from step (f); h) Quantify the fluorescence intensity signal.

[0058] In another embodiment, the test sample for the immunoassay is serum or plasma. In another further embodiment, the secondary antibody fluoresces in the red light spectrum, preferably at 650nm, and the control antibody fluoresces in the green light spectrum, preferably at 550nm. In another further embodiment, the secondary antibody used was anti-IgG-DyLight®650 and the control antibody was anti-HA-DyLight®550. Use of peptide microarray plates to differentiate PV from NV individuals for Yellow Fever

[0059] In one embodiment, the microarray plate is used to differentiate PV from NV individuals for Yellow Fever. Petition 870260057968, dated 06 / 15 / 2026, p. 39 / 78 34 / 69

[0060] In another embodiment, the microarray comprises at least two of the sequences, preferably from SEQ ID No. 1 to SEQ ID No. 49. Kit for serological assessment of vaccination status for Yellow Fever.

[0061] In one embodiment, the kit comprises at least: (a) a peptide microarray plate as defined above; (b) secondary anti-IgG antibody conjugated with fluorescent molecules; and (c) anti-HA control antibody conjugated with fluorescent molecules.

[0062] The kit in question may additionally contain any of the following: blocking solution, immersion solution, washing solution, incubation apparatus and accessories.

[0063] Preferably, the secondary antibody can be anti-IgGDyLight®650 and the control antibody can be anti-HA-DyLight®550, since different fluorescent molecules can be used for the aforementioned antibodies according to the particularities of the scanning equipment used.

[0064] The aforementioned process allows differentiating primary vaccinated individuals (PV) from non-vaccinated individuals (NV) based on the quantification of the intensity of the fluorescence signal emitted by each spot of the VFA Peptide Microarray. EXAMPLES

[0065] The present study was designed with a descriptive-analytical approach to assess vaccination serological status. Petition 870260057968, dated 06 / 15 / 2026, p. 40 / 78 35 / 69 anti-yellow fever 17DD using the VFA Peptide Microarray. The study was structured in the following steps described below: i) Development of a solid support containing microarrays of peptides from the yellow fever vaccine 17DD; ii) Optimization of critical steps for performing the immunoassay using VFA Peptide Microarrays; iii) Initial performance evaluation of the immunoassay using VFA Peptide Microarrays; iv) Validation of the VFA Peptide Microarray model initially proposed for the evaluation of the serological status of the yellow fever vaccine 17DD in different biorepositories; v) Exploratory analysis of the results obtained using the VFA Peptide Microarray employing robust statistical performance analysis tools;vi) Strategies for optimizing the performance of VFA Peptide Microarrays using the common peptide set and the set formed by joining peptides in Biorepository #1 (controlled study) and Biorepository #2 (real-world study); vii) Strategies for optimizing the costs of VFA Peptide Microarrays using minimal peptide selections; viii) Comparative mapping of peptides from the original Microarray and the optimized Peptide Microarrays along the VFA-17DD polyprotein; and ix) Reproducibility, concordance, and interchangeability of peptide recognition by paired serum and plasma samples tested in the VFA Peptide Microarray. VFA Peptide Microarray

[0066] The inventors of the present application performed an in silico prediction of linear B-cell epitopes present in the amino acid sequence of the precursor polyprotein of the Yellow Fever vaccine virus. Petition 870260057968, dated 06 / 15 / 2026, page 41 / 78 36 / 69 strain 17DD, under accession number AAZ07885.1 deposited at the National Center for Biotechnology Information (NCBI).

[0067] The prospecting of linear B-cell epitopes was performed using three predictors, FBCPred (EL-MANZALAWY et al., 2008a), BCPred (EL-MANZALAWY et al., 2008b), which constitute the BCPREDS server (Artificial Intelligence Research Lab, Pennsylvania State University, USA), and BepiPred 1.0 (LARSEN et al., 2006 - Department of Bio and Health Informatics, Technical University of Denmark, DK). Predictions were performed for the prospecting of yellow B-cell linear epitopes and based on two primary parameters: size (15 amino acid residues) and score of the predicted peptides with a specificity of 75% (Figure 1).

[0068] The yellow fever epitopes selected by the inventors were used to construct the VFA Peptide Microarray and its device. These epitopes were adsorbed in duplicate onto the microarray. The devices consist of 25 x 75 mm optical microscopy slides containing five identical copies of the microarray with the 726 epitopes derived from the various compartments of the yellow fever vaccine virus 17DD polyprotein. Each copy of the microarray allows the analysis of one sample, therefore the device allows the evaluation of 5 samples at a time (Figures 2 and 3).

[0069] Each microarray is framed by 44 spots containing poliomyelitis peptide, KEVPALTAVETGAT, and 46 spots containing Influenza Virus (HA) hemagglutinin peptide, YPYDVPDYAG, configuring the sample and analytical controls of the assay, respectively, and 90 spots of glycine (G) compound peptides used as spacers. Petition 870260057968, dated 06 / 15 / 2026, page 42 / 78 37 / 69 These controls were employed for proper alignment of the peptide mesh for subsequent quantification of the fluorescence signal intensity. Figure 2 shows a model of the VFA Peptide Microarray device and accessories for the immunoassay. The PEPperCHIP® 3 / 5 Incubation Apparatus (i.e., supports the use of slides containing 5 microarrays each) consists of an incubation plate, a compatible silicone seal, a fixation support, and a lid, being compatible with 3 devices (slides) and allowing the use of up to 15 samples at a time (Figure 2). Biorepositories

[0070] Biological samples are sourced from three distinct biorepositories. For the purposes of validating the VFA Peptide Microarray, exploratory analysis with robust statistical tools, and cost optimization, serum samples from Biorepository #1 and Biorepository #2 were used. For the steps of reproducibility, concordance, and interchangeability of peptide recognition by paired serum and plasma samples, samples from Biorepository #3 were used.

[0071] Biorepository #1 consists of 15 healthy young adult male volunteers, aged 18, recruits from military units participating in the study “17DD Yellow Fever vaccine: a double-blind, randomized clinical trial of immunogenicity and safety on a dose-response study”. This is a non-inferiority, randomized, double-blind study conducted in Rio de Janeiro / RJ in 2009. Peripheral blood samples, without anticoagulant, were collected before receiving the 17DD yellow fever vaccine (NV) and 30-45 days after primary 17DD yellow fever vaccination (PV). These individuals received the yellow fever vaccine with a concentration of viral particles. Petition 870260057968, dated 06 / 15 / 2026, page 43 / 78 38 / 69 known (approximately 27,476 IU), therefore considered a controlled study (MARTINS et al., 2013).

[0072] Biorepository #2 is derived from 9 volunteers, 4 men and 5 women aged between 50 and 67 years, from the study “Planned yellow fever primary vaccination is safe and immunogenic in patients with autoimmune diseases: a prospective non-interventional study”, a prospective non-interventional study conducted between March 2017 and July 2017 in Vitória, Espírito Santo (ES), Brazil. All participants received the 17DD-FA primary vaccination (Bio-Manguinhos-FIOCRUZ) during the 2017 Brazilian yellow fever vaccination campaign, coordinated by the Government of the State of ES. Peripheral blood samples, without anticoagulant, were collected before receiving the 17DD yellow fever vaccine (NV) and 30-45 days after the 17DD yellow fever primary vaccination (PV). These individuals received the 17DD yellow fever vaccine available in the Unified Health System (SUS), with an unknown concentration of viral particles, therefore considered a real-life study (VALIM et al., 2020).

[0073] Biorepository #3 consists of 6 volunteers, 1 man and 5 women, aged between 27 and 82 years from the study “Heparin removal by ecteola-cellulose pre-treatment enables the use of plasma samples for accurate measurement of anti-Yellow fever virus neutralizing antibodies”. A study conducted in 2013 and 2014 in the cities of Bambuí / Minas Gerais and Vitória / Espírito Santo. Paired samples of peripheral blood were collected with and without heparin anticoagulant (CAMPIAZEVEDO et al., 2017).

[0074] The plaque reduction neutralization test (PRNT) was performed to evaluate neutralizing antibody titers. Petition 870260057968, dated 06 / 15 / 2026, page 44 / 78 39 / 69 specific for Yellow Fever. For the analysis of the data obtained with the PRNT, a cut-off was standardized in order to segregate those individuals who had seroconverted after primary vaccination, being defined as >2.7 log10 mUI / mL, equivalent to 1:50 of the reciprocal of the dilution. This test was performed as an eligibility criterion. All those included were considered seronegative for Yellow Fever before primary vaccination and were considered seropositive 30-45 days after primary vaccination.

[0075] The list of volunteers included in Biorepository #1, Biorepository #2 and Biorepository #3, with their respective PRNT values, are found in Tables 2, 3, and 4, respectively. Table 2: Relationship of Serum Samples from Volunteers Included in Biorepository #1 (controlled study) and PRNT Titers. Relationship of paired samples from Biorepository #1 (controlled study). Peripheral blood samples were collected before (NV) and 30-45 days after primary yellow fever vaccination (PV). Neutralizing antibody titers (PRNT) were determined before and 30-45 days after primary yellow fever vaccination. Source: MARTINS, 2013. Samples NV Age (years) Sex PRNT Titers (log™ mUI / mL) Samples PV PRNT Titers (log™ mUI / mL) 22366 18 M 1.82 21971 3.26 20633 18 M 2.57 21054 3.30 22595 18 M 2.42 22893 3.38 20580 18 M 1.68 21019 3.44 20437 18 M 1.96 22271 3.47 21403 18 M 1.84 22852 3.63 21891 18 M 2.01 22266 3.73 Petition 870260057968, dated 06 / 15 / 2026, page 45 / 78 40 / 69 20605 18M 1.96 20945 3.80 20044 18M 2.54 20737 3.91 20444 18M 2.47 22362 3.97 21302 18M 2.34 21931 4.11 20612 18M 2.27 21047 4.18 21135 18 M 2.17 22243 4.30 20602 18 M 1.96 21021 4.37 21380 18 M 2.55 21791 4.50 Table 3: Relationship of Serum Samples from Volunteers Included in Biorepository #2 (real-life study) and PRNT Titers. Relationship of paired samples from Biorepository #2 (real-life study). Peripheral blood samples were collected before (NV) and 30-45 days after primary yellow fever vaccination (PV). Neutralizing antibody titers (PRNT) were determined before and 30-45 days after primary yellow fever vaccination. Source: VALIM, 2020. Samples NV Age (years) Sex PRNT Titers (Inverse of dilution) Samples PV PRNT Titers (Inverse of dilution) CO02 56 F 5 CO02 640 CO17 61 M 5 CO17 640 CO21 66 M 5 CO21 640 CO22 63 M 5 CO22 640 CO24 60 F 7 CO24 640 CO25 50 F 5 CO25 568 CO29 51 F 33 CO29 640 CO30 67 F 5 CO30 640 CO50 50 M 6 CO50 314 Table 4 - Relationship between Serum and Plasma Samples from Volunteers Included in Biorepository #3 (serum x plasma) and PRNT Titers. Relationship between paired samples from Biorepository #3 (serum x plasma). Paired samples of peripheral blood with anticoagulant were collected. Petition 870260057968, dated 06 / 15 / 2026, page 46 / 78 41 / 69 heparin and no anticoagulant. Neutralizing antibody titers (PRNT) were determined for serum and plasma samples. Source: CAMPIAZEVEDO, 2017. Serum Samples Age (years) Sex PRNT Titers (Inverse of dilution) Plasma Samples PRNT Titers (Inverse of dilution) 17 - MG 45 F 23 17 - MG 80 7 - MG 60 F 17 7 - MG 84 16 - MG 82 M 16 16 - MG 66 ACZ - ES 27 F 5 ACZ - ES 5 RAS - ES 49 F 5 RAS - ES 5 RS - ES 38 F 5 RS - ES 5

[0076] The inclusion criteria used for Biorepository #1 and Biorepository #2 for volunteers in the NV group were: no history of 17DD yellow fever vaccination prior to inclusion in the study; having negative neutralizing antibody levels (less than 2.7 log10 mUI / mL for Biorepository #1 and less than 1:50 of the reciprocal of the dilution for Biorepository #2) prior to primary 17DD yellow fever vaccination; accepting and signing the informed consent form (ICF).

[0077] The inclusion criteria used for Biorepository #1 and Biorepository #2 for PV group volunteers were: no history of 17DD yellow fever revaccination; positive neutralizing antibody levels (greater than or equal to 2.7 log10 mUI / mL for Biorepository #1 and greater than or equal to 1:50 of the reciprocal of the dilution for Biorepository #2) 30-45 days after primary 17DD yellow fever vaccination; no participation in military missions or travel to wilderness areas for Biorepository #1.

[0078] It is worth noting that the unit of measurement for PRNT of the samples from Biorepository #1 and Biorepository #2 are different because, in 2009, the control serum from vaccinated monkeys provided by the WHO was still being used, because Petition 870260057968, dated 06 / 15 / 2026, page 47 / 78 42 / 69 PRNT results were released in log mUI / mL. In 2017, the WHO no longer provided this control serum, so PRNT results began to be released as the reciprocal of the dilution.

[0079] The inclusion criteria used for Biorepository #3 were having paired serum and heparinized plasma samples (collected on the same day), and accepting and signing the Informed Consent Form. Example 1 Immunoassay for evaluating the peptide recognition repertoire.

[0080] The evaluation of the peptide recognition repertoire by serum and plasma samples collected before (NV) and after primary yellow fever vaccination (PV) was performed using the customized VFA Peptide Microarray system (PEPperPRINT GmbH, Heidelberg, DE). The operating protocol provided by the manufacturer is available at: The manual for the scanner used to quantify the fluorescence signal intensity is available at: https: / / www.sicasys.de / pepslide / manuals / .

[0081] The protocol recommended by the manufacturer PEPperPRINT® advocates the use of a wide range of sample dilutions (1:10 to 1:10,000) and secondary antibody dilutions (1:500 to 1:10,000) for performing the immunoassay. The user manual for the peptide microarray scanner (SureScan Microarray Scanner G4900DA, Agilent, Santa Clara, CA, USA) recommends using the photomultiplier tube (PMT) sensitivity at 100%. Petition 870260057968, dated 06 / 15 / 2026, page 48 / 78 43 / 69 However, both the microarray manufacturer and the scanner's user manual recommend optimizing parameters for performing immunoassays on customized peptide microarrays.

[0082] Previously, the inventors of the present application, in a joint analysis of the critical optimization steps of the VFA Peptide Microarray operational protocol, established the following conditions for standardization of the immunoassay: sensitivity level of the photomultiplier tube of 50% (PMT 50), dilution of the anti-IgG-DyLight®650 secondary antibody 1:5,000 and sample dilution 1:500. Sample Thawing and Sample and Antibody Dilution

[0083] Serum or plasma samples were removed from the freezer at -80°C and kept on ice until thawed. Then, the samples were vortexed homogenized for 5 seconds and centrifuged for 10 minutes at 14,000 xg at room temperature (RT). They were then subjected to a 1:500 dilution in labeling buffer (PBS 1X buffer - Phosphate Buffered Saline, pH 7.4; 0.1% Tween 20 and 0.5% BSA - Bovine Albumin Serum). The secondary antibodies were also diluted in labeling buffer, with the anti-IgGDyLight®650 antibody diluted 1:5,000 and the anti-hemagglutinin control antibody for Influenza Virus (anti-HA-DyLight®550) diluted 1:2,000. These dilutions were standardized by the inventors of the present application.

[0084] Figure 2C represents the standard operating protocol of VFA Peptide Microarray according to the manufacturer PEPperPRINT®, divided into three stages: 1) Pre-labeling with the secondary antibody anti-IgGDyLight®650; Petition 870260057968, dated 06 / 15 / 2026, page 49 / 78 44 / 69 2) Incubation with a serum or plasma test sample, followed by incubation with the anti-IgG-DyLight®650 secondary antibody; 3) Labeling with anti-HA-DyLight®550 control antibody.

[0085] In steps 1 and 2, the slides were scanned in the red channel (anti-IgG-DyLight®650) and in step 3, the slides were scanned in the green channel (anti-HA-DyLight®550). Finally, the respective images of the slides were obtained using the SureScan Microarray Scanner G4900DA, in TIFF file format, for quantification of the fluorescence signal intensity. Pre-labeling with anti-IgG secondary antibody - DyLight®650

[0086] Pre-labeling with the secondary antibody aims to monitor any non-specific interactions of the secondary antibody with the peptides printed on the microarray slides. The slides were incubated for 15 minutes in an orbital shaker (Nova Instruments - Model NI1154) at 200 rpm, in room temperature with 500 pL of washing buffer (PBS 1X, pH 7.4, 0.1% Tween 20). Then, they were incubated for 30 minutes in a microplate orbital shaker at 200 rpm, in room temperature with 500 pL of blocking buffer (PBS 1X, pH 7.4, 0.1% Tween 20 and 5% BSA).

[0087] After blocking, the slides were incubated, protected from light, with 200 pL of anti-IgG-DyLight®650 secondary antibody (SA5-10137, ThermoFisher Scientific, Waltham, MA, USA) previously diluted 1:5,000 in labeling buffer, for 45 minutes in a microplate orbital shaker at 200 rpm, at room temperature.

[0088] Next, the slides were washed five times for two minutes in an orbital microplate shaker at 200 rpm in room temperature with 500 µL of washing buffer. Then, the slides were removed from the apparatus. Petition 870260057968, dated 06 / 15 / 2026, pp. 50 / 78 The slides were incubated for 45 / 69 minutes and submerged three times in a beaker containing immersion buffer (1 mM Tris, pH 7.4). Drying consisted of centrifuging them for two minutes at 900 x g at room temperature, and then carefully placed in 50 mL polypropylene tubes, protected from light. Subsequently, they were prepared for reading on the SureScan scanner. The slides were immediately scanned in the red channel (DyLight® 650) at a resolution of 5 pm. The images were exported and stored in 16-bit TIFF format for later analysis using the PepSlide® Analyzer program, version 2.2.8 (PEPperPRINT GmbH, Heidelberg, DE). Incubation with test samples and with anti-IgGDyLight®650 secondary antibody

[0089] After the pre-labeling step with the anti-IgG-DyLight®650 secondary antibody, the slides were subjected to a new 15-minute incubation in an orbital microplate shaker at 200 rpm, in room temperature with 500 pL of labeling buffer and subsequently incubated with 200 pL of serum or plasma samples diluted 1:500 in labeling buffer for 15 hours at 200 rpm, 2°C to 8°C. After incubation, the slides were washed five times for two minutes, under agitation at 200 rpm, in room temperature with 500 pL of washing buffer and then incubated again for 45 minutes under agitation, in room temperature, with 200 pL of labeling buffer containing anti-IgG-DyLight®650 secondary antibody, diluted 1:5,000.

[0090] The slides were washed five times for two minutes, as described previously. Then, the slides were removed from the incubation apparatus and submerged three times in a beaker containing immersion buffer (1mM Tris, pH 7.4), followed by drying. Subsequently, they were prepared for reading on the SureScan scanner. The slides were Petition 870260057968, dated 06 / 15 / 2026, page 51 / 78 46 / 69 immediately scanned in the red channel (DyLight®650) at a resolution of 5 μm. The images were exported and stored in 16-bit TIFF file format for later analysis using the PepSlide® Analyzer program. Antibody labeling with anti-HA control antibody - DyLight® 550

[0091] After the second scan of the slides, they were incubated for 15 minutes in an orbital shaker and subsequently incubated for 45 minutes with 200 pL of anti-HADyLight®550 control antibody diluted 1:2,000 in labeling buffer. Then, the slides were removed from the incubation apparatus and submerged three times in a beaker containing immersion buffer and subsequently centrifuged for drying, as previously described, and prepared for reading on the SureScan scanner. The slides were scanned in the green channel (DyLight®550) at a resolution of 5 μm. Alternatively, the slides were kept at room temperature for up to 2 hours or stored at 2°C to 8°C for up to seven days before scanning for the anti-HA control antibody labeling. The images were exported and stored in 16-bit TIFF format for later analysis using PepSlide® Analyzer software. Quantification of peptide recognition by samples

[0092] The quantification of peptide recognition by serum or plasma samples was based on the quantification of the intensity of the red fluorescence signal (DyLight®650) emitted by each spot of the VFA Peptide Microarray. This procedure was performed using the PepSlide® Analyzer program (Sicasys Software GmbH, Heidelberg, Germany), according to the manufacturer's recommendations, available at: https: / / www.sicasys.de / pepslide / manuals / . Petition 870260057968, dated 06 / 15 / 2026, page 52 / 78 47 / 69

[0093] The TIFF images were imported into the aforementioned program and the red fluorescence channel was selected for evaluation of the fluorescence signal intensity obtained in the pre-labeling steps with DyLight®650 anti-IgG secondary antibody and incubation with sample and DyLight®650 anti-IgG secondary antibody. Subsequently, the automatic brightness and contrast adjustment function was used to optimize spot visualization and alignment of the VFA Peptide Microarray layout.

[0094] The fluorescence signal intensity values ​​were quantified using the Quantify function. To obtain the median fluorescence signal intensity values ​​for each spot, the Foreground 1 and Foreground 2 values ​​were calculated. For the calculation of the Foreground 1 and Foreground 2 values, the Raw Data 1 (I + II) and Background 1 (II) values ​​were previously obtained, which refers to the signal intensity of the pre-labeling step with anti-IgG DyLight®650 secondary antibody, and the Raw Data 2 (I + II) and Background 2 (II) values, which refers to the signal intensity of the incubation step with sample and secondary antibody (Figures 3B and 3C).

[0095] The values ​​of Foreground 1 and Foreground 2 were calculated according to the equations below: Foreground 1 (Pre-Marking Stage) = Raw Data Value 1 - Background Value 1 Foreground 2 (Incubation Stage) = Raw Data Value 2 - Background Value 2 Petition 870260057968, dated 06 / 15 / 2026, page 53 / 78 48 / 69

[0096] Foreground 1 refers to the value of nonspecific interactions of the secondary antibody with the epitopes printed on the slide, and Foreground 2 corresponds to the value of specific interactions of the serum or plasma samples with the peptides printed on the microarray. The files containing the Foreground 1 and Foreground 2 values ​​in CSV format were imported into Microsoft Excel (2019) to calculate the result according to the following equation: Result = Foreground 2 - Foreground 1

[0097] The resulting fluorescence intensity for each spot is calculated by the difference between the Foreground 2 and Foreground 1 values. The final fluorescence intensity for each peptide was calculated by averaging the values ​​resulting from duplicates of each spot. Any negative values ​​were considered as zero. Figure 3 shows the elements used to calculate the Resultant. Example 2 - Validation of the model proposed by the inventors of this application for the evaluation of 17DD yellow fever vaccine serological status using the VFA Peptide Microarray

[0098] An exploratory analysis of the recognition of VFA precursor polyprotein peptides by paired samples of unvaccinated (NV) and primary (PV) individuals with 17DD yellow fever vaccine from Biorepository #1 was performed to assess 17DD yellow fever vaccination serological status. Using VFA Peptide Microarray methodology and different fluorescence intensity thresholds [IF> (0) / (5) / (20)], a model using #149 peptides was proposed to classify NV and PV individuals with high accuracy (Sen and Petition 870260057968, dated 06 / 15 / 2026, pp. 54 / 78 49 / 69 (Esp=100%). The model was used to evaluate the recognition of peptides by serum samples using three fluorescence intensity thresholds, encompassing the total set of #149 peptides: IF>0 (57 peptides), IF>5 (48 peptides) and IF>20 (44 peptides).

[0099] In order to validate the proposed model, #149 peptides were used to evaluate the 17DD yellow fever vaccine serological status of paired samples from unvaccinated (NV) and primary (PV) individuals with 17DD yellow fever vaccine in assays using samples from Biorepository #2 (real-world study, NV=9 and PV=9). The results of this validation step are presented in Figure 4.

[00100] Data analysis demonstrated that although the #149 peptide model showed high performance (Sen and Esp=100%, AUC=1.00) for classifying paired samples of NV and PV individuals from Biorepository #1 (controlled study), the microarray performance was lower (Sen=100%, Esp=0%, AUC=0.61) using paired samples of NV and PV individuals from Biorepository #2 (real-world study). Example 3 - Exploratory analysis of peptide recognition by samples from Biorepository #1 and Biorepository #2 using the VFA Peptide Microarray

[00101] For the exploratory analysis of peptide recognition by paired samples from Biorepository #1 (controlled study; NV=15 and PV=15) and Biorepository #2 (real-life study; NV=9 and PV=9), fluorescence intensity (FI) point distribution plots were constructed for individual samples to obtain a panoramic view of the recognition of the 726 peptides. The peptide ordering was Petition 870260057968, dated 06 / 15 / 2026, pp. 55 / 78 50 / 69 determined according to its location in the precursor polyprotein of the yellow fever vaccine virus 17DD. The results of this evaluation are presented in Figure 5.

[00102] The IF, which represents the recognition of each peptide by individual samples from Biorepository #1 and Biorepository #2, expressed in arbitrary units (AU), was used to characterize the panoramic profile of the recognition of the 726 peptides (Figure 5). Visual exploratory analysis of the results allowed the identification of sets of peptides differentially recognized by serum samples from Biorepository #1 and Biorepository #2 (elliptical shapes). Additionally, some sets of peptides showed a preferential recognition profile by PV samples in both biorepositories (rectangular shapes). However, the similarity between the IF values ​​of NV and PV demonstrated the need to use robust statistical performance analysis tools to define IF thresholds for the identification of peptides with specific recognition by PV samples.Example 4 - Analysis of peptide recognition by samples from Biorepository #1 and Biorepository #2 in the VFA Peptide Microarray using robust statistical performance analysis tools.

[00103] Figure 6 demonstrates the analysis model used to evaluate the recognition of each of the #726 peptides by individual NV and PV samples from Biorepository #1 and Biorepository #2. Peptide recognition showed a particular profile, with varying performance in distinguishing the reactivity of samples from Biorepository #1 and Biorepository #2. The use of tools Petition 870260057968, dated 06 / 15 / 2026, pp. 56 / 78 51 / 69 robust statistics demonstrated that the same peptide may require different fluorescence intensity thresholds to segregate NV and PV samples from Biorepository #1 and Biorepository #2. The ROC curves illustrate the IF thresholds that classified NV or PV samples with their respective performance indices (AUC, Sen, and Esp).

[00104] As exemplified in Figure 6, peptide #640 showed selectivity for PV samples from both biorepositories, however, requiring the use of different IF thresholds. On the other hand, peptide #137 showed selectivity for PV samples in Biorepository #1, being specific for NV samples in Biorepository #2 (Figure 6B, elliptical shape).

[00105] TG-ROC curves were employed to analyze the recognition of each of the #726 peptides by individual NV and PV samples from Biorepository #1 and Biorepository #2 in order to identify valid IF threshold zones with constant performance indices. The identification of valid IF threshold zones was a rational strategy to support the search for common IF thresholds to be used in the correct classification of PV samples from both biorepositories.

[00106] Once the IF thresholds for each of the #726 peptides and their performance for the correct classification of PV samples from both biorepositories were identified, the PV-specific peptides were grouped into 12 matrices of different fluorescence intensity thresholds (IF>0, IF>5, IF>10, IF>20, IF>30, IF>40, IF>50, IF>100, IF>200, IF>500, IF>1000, IF>2000) for samples from Biorepository #1 and Biorepository #2. The results are shown in Figure 7. Petition 870260057968, dated 06 / 15 / 2026, pp. 57 / 78 52 / 69

[00107] To prevent redundant inclusion of peptides, peptides present in more than one IF threshold matrix were included only in the first matrix with the lowest IF threshold. For example, the IF>0 matrix includes the set of peptides identified exclusively at the IF>0 threshold, as well as those peptides identified simultaneously at another higher threshold(s). This continues successively until the IF>2000 matrix, which includes only the set of peptides identified exclusively at the IF>2000 threshold.

[00108] The use of robust statistical tools allowed the identification of #239 PV-specific peptides for the correct classification of samples from Biorepository #1 and #144 PV-specific peptides for samples from Biorepository #2 (Figure 7A).

[00109] Next, the performance of the VFA Peptide Microarray was evaluated using the #239 PV-specific peptide set from Biorepository #1 (controlled study) and the #144 PV-specific peptide set from Biorepository #2 (real-life study). The results are presented in Figure 7B.

[00110] Data analysis demonstrated that models using different IF thresholds combined [Σ>(0) / (5) / ( 10) / (20) / (30) / (40) / (50) / (100) / (200) / (500) / (1000) / (2000)] showed excellent performance (AUC=1.00) in segregating NV and PV individuals according to their 17DD yellow fever vaccination serological status in both biorepositories. The ROC curve illustrates the high performance indices (AUC, Sen and Esp). Petition 870260057968, dated 06 / 15 / 2026, pp. 58 / 78 53 / 69 Example 5 - Strategies for optimizing the performance of the VFA Peptide Microarray

[00111] In order to identify the set of peptides capable of correctly classifying PV samples, two analysis strategies were performed with the aim of optimizing the performance of the VFA Peptide Microarray. The results are presented in Figures 8 and 9.

[00112] In the first strategy, the Venn Diagram analysis model was applied to identify the set of peptides commonly reactive to PV serum samples from both Biorepository #1 and Biorepository #2, capable of correctly classifying PV samples from these two biorepositories, with their respective IF thresholds. The schematic Venn Diagram model employed the set of #239 PV-specific peptides from Biorepository #1 (controlled study) and the set of #144 PV-specific peptides from Biorepository #2 (real-life study) for the selection of the common peptide set. The results are presented in Figure 8. #45 common peptides, reactive to PV serum samples from both biorepositories, capable of correctly classifying PV samples, were identified.However, only 8 peptides were at the same IF threshold for correct classification of PV samples in both biorepositories (5 peptides IF>0 and 3 peptides IF>5). The use of the VFA Peptide Microarray with 8 peptides did not perform well using PV samples from Biorepository #1 (Sen=53% and Esp=100%). Biorepository #2 (Sen=44% and Esp=100%) or both biorepositories (Sen=50% and Esp=100%). (Data not shown). Petition 870260057968, dated 06 / 15 / 2026, pp. 59 / 78 54 / 69

[00113] Thus, it was necessary to use complementary analysis approaches using the #45 common peptides. Through statistical tools, based on the concepts of the TG-ROC Curve and ROC Curve, as shown in Figure 6 which exemplifies the individual behavior of peptide #640, the lowest and highest IF thresholds were identified for each of the #45 PV-selective peptides. The first approach consisted of using the #45 peptides employing the lowest IF thresholds in order to guarantee greater test sensitivity. For example, a PV-specific peptide with an IF threshold >20 in Biorepository #1 and with an IF threshold >500 in Biorepository #2 was used in the first approach, using the IF threshold >20 for both biorepositories. The second approach consisted of using the #45 peptides employing the highest IF thresholds as a rationale to guarantee greater specificity.For example, a PV-specific peptide with an IF>10 threshold in Biorepository #1 and an IF>200 threshold in Biorepository #2 was employed in the second approach, using the IF>200 threshold for both biorepositories.

[00114] The results demonstrated that the first approach using the #45 peptides and the lowest IF thresholds did not allow for the correct classification of NV and PV samples, with a high rate of incorrect classification of NV samples as positive in both biorepositories (Figure 8B, elliptical shapes). Although most PV samples were correctly classified in both biorepositories (Sen=87% and Sen=100%, respectively), only 20% of NV samples were correctly classified in Biorepository #1 and none were correctly classified in Biorepository #2. On the other hand, in the second Petition 870260057968, dated 06 / 15 / 2026, pp. 60 / 78 55 / 69 approach using the #45 peptides and the highest IF thresholds, correct classification of NV and PV samples occurred with high accuracy in both biorepositories (Sen=80% and 89%, respectively and Esp=100% in both biorepositories) (Figure 8B).

[00115] In a complementary analysis, the overall performance of the #45 peptide set was evaluated for the classification of all samples from Biorepository #1 (controlled study; NV=15 and PV=15) and Biorepository #2 (real-world study; NV=9 and PV=9). The results are shown in Figure 8C. The data confirmed that the use of the first approach using the #45 peptides and the lower IF thresholds did not allow for the correct classification of NV and PV samples, with a high rate of incorrect classification of NV samples as positive in both biorepositories (Figure 8C, elliptical shape). Although most PV samples were correctly classified (Sen=92%), only 14% of NV samples were correctly classified.Again, in the second approach, the use of the #45 peptides and the higher IF thresholds allowed for the correct classification of NV and PV samples with high accuracy (Sen=83% and Esp=100% for the set of samples from both biorepositories) (Figure 8C).

[00116] In a second strategy, with the intention of further improving the assay performance, the model that used the set formed by the union of reactive peptides to PV serum samples from Biorepository #1 and Biorepository #2 was applied, without redundancy, capable of correctly classifying the PV samples, with their respective IF thresholds. The results are presented in Figure 9. Petition 870260057968, dated 06 / 15 / 2026, pp. 61 / 78 56 / 69

[00117] The union of peptides capable of correctly classifying PV samples, originating from Biorepository #1 and Biorepository #2, without redundancy, resulted in #338 peptides (#239 + #144 - #45 redundant peptides) (Figure 9A). It was necessary to subtract #45 redundant peptides, as they were counted twice.

[00118] Next, peptides that showed reactivity when using samples from NV individuals from Biorepository #1 and Biorepository #2 were excluded. The exclusion was performed using Microsoft Excel (2019), by searching for PV-reactive peptides in both biorepositories. PV-reactive peptides in only one of the biorepositories were disqualified, resulting in #99 PV-reactive peptides using the lowest IF threshold and #136 PV-reactive peptides using the highest IF threshold. In this peptide pooling strategy, two analysis approaches were used. The first approach involves using #338 peptides and the lowest IF thresholds to ensure greater test sensitivity. The second approach involves the use of #338 peptides and the application of higher IF thresholds, in order to ensure greater test specificity.Reactive peptides with NV samples from Biorepository #1 and Biorepository #2 were excluded. After exclusion, a search for PV-reactive peptides in both biorepositories was performed using Microsoft Excel (2019). PV-reactive peptides in only one of the biorepositories were disqualified, resulting in #136 PV-reactive peptides using the highest IF threshold. Petition 870260057968, dated 06 / 15 / 2026, pp. 62 / 78 57 / 69

[00119] The results demonstrated that in both approaches (#99 peptides and #136 peptides) the correct classification of NV samples (Esp=100%) and most PV samples from Biorepository #1 (Sen=87%) and Biorepository #2 (Sen=100%) occurred (Figure 9B).

[00120] In a complementary analysis, the overall performance of the sets of #99 peptides (lower IF thresholds) and #136 peptides (higher IF thresholds) was evaluated for the classification of the total samples from Biorepository #1 (controlled study; NV=15 and PV=15) and Biorepository #2 (real-life study; NV=9 and PV=9). The results are shown in Figure 9B. The data demonstrated that the use of both approaches (#99 peptides and #136 peptides) allowed for the correct classification of NV and PV samples, with high accuracy (Sen=92% and Esp=100% for the set of samples from both biorepositories). The results are shown in Figure 9C.

[00121] The use of optimization strategies, employing valid zones of lower or higher IF thresholds, identified #45 common peptides with high performance (Sen=83% and Esp=100%) (Figure 8). However, peptide pooling (#99 or #136 peptides) increased the performance of the VFA Peptide Microarray (Sen=92% and Esp=100%) (Figure 9) for correct classification of PV samples from the controlled study and the real-life biorepository. Example 6 Strategies for Optimizing the Costs of VFA Peptide Microarrays Using a Minimum Selection of Peptides with Lower and Higher IF Thresholds Petition 870260057968, dated 06 / 15 / 2026, pp. 63 / 78 58 / 69

[00122] In order to reduce the cost of the VFA Peptide Microarray, a further step was carried out to identify a minimum selection of peptides capable of correctly classifying NV and PV samples from Biorepository #1 (controlled study) and Biorepository #2 (real-life study). The results are presented in Figure 10.

[00123] Aiming at cost optimization, the two previously used analysis approaches were applied: the set of #99 peptides (lowest IF thresholds) and the set of #136 peptides (highest IF thresholds). In both approaches, optimization was performed to maintain the performance of the VFA Peptide Microarray. The results are shown in Figure 10. The cost optimization results demonstrated that from the set of #99 (lowest IF thresholds), the minimum selection resulted in #47 peptides capable of correctly classifying the PV samples. For the set of #136 (highest IF thresholds), the minimum selection resulted in #49 peptides capable of correctly classifying the PV samples (Figure 10A).

[00124] The results demonstrated that in both approaches (#47 peptides and #49 peptides) the correct classification of NV samples (Esp=100%) and most PV samples from Biorepository #1 (Sen=87%) and Biorepository #2 (Sen=100%) occurred. The results are shown in Figure 10B.

[00125] In a complementary analysis, the overall performance of the sets of #47 peptides (lower IF thresholds) and #49 peptides (higher IF thresholds) was evaluated for the classification of the total samples from Biorepository #1 (controlled study; NV=15 and PV=15) and Biorepository #2 (real-life study; NV=9 and PV=9). The results are Petition 870260057968, dated 06 / 15 / 2026, pp. 64 / 78 59 / 69 shown in Figure 10C. The data demonstrated that the use of the two approaches (#47 peptides and #49 peptides) allowed for the correct classification of NV and PV samples, with high accuracy (Sen=92% and Esp=100%) for the set of samples from both biorepositories. Example 7 - Comparative performance and estimated costs of Optimized VFA Peptide Microarrays

[00126] Figure 11 shows a comparison of the performance and cost values ​​of the optimized VFA Peptide Microarrays. The results demonstrated that the optimized microarrays #99 and #136 (union of peptides from the two biorepositories), #47 and #49 (minimal peptide selection) showed superior performance (Sen=92% and Esp=100%) compared to the microarray employing #45 peptides reactive to samples from both biorepositories (Sen=83% and Esp=100%).

[00127] From a financial standpoint, optimizing the costs of the VFA Peptide Microarray represented a significant gain. A comparative analysis of the estimated cost of assays employing the original microarray of #726 peptides and the optimized microarrays: #45 (common peptides in both biorepositories), #99 and #136 (union of non-redundant peptides in both biorepositories), #47 and #49 (minimal peptide selection) is presented in Figure 11B. According to quotations obtained from the microarray slide manufacturer, the estimated cost per slide is US$ 917.00. According to technical consultation with the manufacturer, the number of microarray copies per slide can vary from 1 to 16 depending on the number of peptides included in each microarray. Microarrays containing a set of peptides less than 120 can be assembled in 16 copies per slide. Based on this information, selections #45 Petition 870260057968, dated 06 / 15 / 2026, pages 65 / 78 60 / 69 (common peptides in both biorepositories), #47 and #49 (minimal peptide selection) could be assembled in 16 copies per slide, with a final cost of US$ 58.00. However, considering the sensitivity and specificity data obtained in the performance analysis of these selections, the minimal selection models #47 and #49 showed superior accuracy for the correct classification of NV and PV samples from Biorepository #1 and Biorepository #2 (Figure 11 A). Therefore, the application of additional cost optimization tools for the VFA Peptide Microarray selected minimal selections of #47 and #49 peptides with high performance (Sen=92% and Esp=100%) to correctly classify PV samples from the controlled study and the real-world biorepository. Example 8 - Comparative mapping of peptides from optimized VFA peptide microarrays along the VFA-17DD polyprotein.

[00128] The original VFA Peptide Microarray proposal was constructed as a serological testing device applied to the identification of unvaccinated (NV) and primary (PV) individuals for Yellow Fever. The original device consisted of a set of peptides identified by in silico screening of linear B-cell epitopes in the predicted proteome of the yellow fever vaccine virus 17DD. The location of the #726 peptides along the VFA-17DD polyprotein is shown in Figure 12A.

[00129] In a comparative analysis, the peptides included in the original proposal and the optimized VFA Peptide Microarrays in this study were mapped. The results are presented in Figure 12A. In the original proposal of 726 peptides, there was a distribution of peptides with a higher concentration in the regions corresponding to the proteins. Petition 870260057968, dated 06 / 15 / 2026, pp. 66 / 78 61 / 69 NS5, E, NS1, and NS3. In selection #45 (common peptides reactive to samples from both biorepositories, with a higher IF threshold), there was a distribution of peptides with a higher concentration in the regions corresponding to the NS5, E, and NS3 proteins. Selection #99 (union of non-redundant peptides in both biorepositories, lower IF threshold) showed a distribution with a higher concentration in the regions corresponding to the NS5, E, and NS1 proteins. The peptides included in selection #136 (union of non-redundant peptides in both biorepositories, higher IF threshold) showed a distribution with a higher concentration in the regions corresponding to the NS5 and E proteins. In the minimum selection #47 (minimum selection of peptides, lower IF threshold), the included peptides showed a distribution with a higher concentration in the regions corresponding to the NS5, E, and NS1 proteins.The minimum selection #49 (minimum peptide selection, highest IF threshold) showed a distribution with a higher concentration in the regions corresponding to the NS5, E, and NS3 proteins. Figures 12B and 12C illustrate this information in a complementary way.

[00130] Comparative mapping analysis demonstrated that, in general, the peptides included in the optimized VFA Peptide Microarrays showed a distribution with a higher concentration in the regions corresponding to the NS5 and E proteins along the VFA-17DD precursor polyprotein, as indicated by the arrows in Figure 12B. Example 9 Reproducibility, concordance, and interchangeability of peptide recognition by serum and plasma samples tested on the VFA Peptide Microarray. Petition 870260057968, dated 06 / 15 / 2026, pages 67 / 78 62 / 69

[00131] In order to evaluate the reproducibility, concordance, and interchangeability of the results obtained in the VFA Peptide Microarray, peptide recognition was comparatively evaluated using paired serum and plasma samples from Biorepository #3 in the original VFA Peptide Microarray and in the optimized VFA Peptide Microarrays. The results are presented in Figure 13.

[00132] Representative images of peptide recognition by paired samples demonstrated the reproducibility of VFA Peptide Microarray results using serum and plasma samples from Biorepository #3. In a panoramic comparative analysis, a similar IF profile was observed in the microarrays demonstrating similar peptide recognition in assays performed with paired serum and plasma samples (Figure 13).

[00133] To confirm the interchangeability of using serum or plasma samples in the VFA Peptide Microarray, the concordance of peptide recognition was evaluated using paired serum and plasma samples from Biorepository #3. For this purpose, the concordance of negativity (-) or positivity (+) in peptide recognition in the VFA Peptide Microarray was evaluated using the Kappa index to compare peptide recognition in the original VFA Peptide Microarray and in the optimized VFA Peptide Microarrays. The data analysis demonstrated substantial concordance between the peptide recognition results by serum and plasma samples in all microarray pairs analyzed (Table 5). Petition 870260057968, dated 06 / 15 / 2026, pages 68 / 78 63 / 69 Table 5: Concordance of Peptide Recognition by Serum and Plasma Samples Tested on Original and Optimized VFA Peptide Microarrays. Data are presented as the number of non-reactive (-) and reactive (+) peptides for each peptide selection using paired serum and plasma samples. Bold and underlined values ​​represent peptides that were equally considered positive or negative in both samples (serum and plasma). The Kappa Index (95% CI) was calculated for each paired analysis. Original Sample Commons Union Minimum Selection #726 #45 HIGHEST IF #99 LOWEST IF #136 HIGHEST IF #47 LOWEST IF #49 HIGHEST IF Serum Serum Serum Serum Serum Serum (-) (+) Kappa (-) (+) Kappa (-) (+) Kappa (-) (+) Kappa (-) (+) Kappa (-) (+) Kappa #01 Asma (-) 294 80 0.67 (0.6-0.7) 20 5 0.65 (0.4-0.9) 50 6 0.81 (0.7-0.9) 64 11 0.75 (0.6-0.9) 21 2 0.87 (0.7-0.0) 21 5 0.67 (0.5-0.9) (+) 40 312 3 17 3 40 6 55 1 23 3 20 #02 Plasma (-) 288 52 0.75 (0.7-0.8) 21 5 0.73 (0.5-0.9) 48 6 0.80 (0.7-0.9) 64 20 0.80 (0.7-0.9) 22 5 0.75 (0.6-0.9) 22 6 0.71 (0.5-0.9) (+) 39 347 1 18 4 41 8 59 1 19 1 20 #03 Amazing (-) 369 46 0.70 (0.7-0.8) 26 1 0.71 (0.5-0.9) 55 6 0.85 (0.8 Io) 73 7 0.80 (0.7-0.9) 27 2 0.91 (0.8-1.0) 27 1 0.74 (0.6-0.9) (+) 57 254 5 13 1 37 6 50 0 18 5 16 #04 Plasma (-) 279 14 0.70 (0.7-0.8) 21 0 0.91 (0.8-1.0) 52 1 0.73 (0.6-0.9) 65 1 0.78 (0.7-0.9) 24 0 0.74 (0.6-0.9) 21 0 0.92 (0.8-1.0) (+) 95 338 2 22 12 34 14 56 6 17 2 26 #05 Plasma (-) 412 23 0.64 (0.6-0.7) 33 1 0.67 (0.4-0.9) 68 2 0.70 (0.6-0.9) 93 3 0.69 (0.6-0.8) 30 1 0.86 (07-1.0) 35 1 0.72 (0.5-0.9) (+) 97 194 4 7 9 20 13 27 2 14 4 9 #06 Plasma (-) 263 62 0.77 (0.7-0.8) 18 3 0.82 (0.7-1.0) 47 8 0.80 (0.7-0.9) 58 11 0.79 (0.7-0.9) 19 1 0.91 (0.8-1.0) 19 3 0.83 (07-1.0) (+) 20 381 1 23 2 42 3 64 1 26 1 26 All Plasma (-) 1905 277 0.71 (0.7-0.7) 139 15 0.76 (0.7-0.8) 320 29 0.79 (0.7-0.8) 417 41 0.78 (0.7-0.9) 138 14 0.81 (0.7-0.9) 145 16 0.78 (0.7-0.8)

[00134] In a complementary analysis, a comparison of peptide recognition levels was performed using paired serum and plasma samples from Biorepository #3, using the sum of the IF values ​​of peptide reactivity. The results are presented in Figure 14. A Petition 870260057968, dated 06 / 15 / 2026, pp. 69 / 78 Analysis of the 64 / 69 data demonstrated that there was no significant difference in the sum of peptide reactivity values ​​using paired serum and plasma samples across all microarrays.

[00135] The comparative study of peptide recognition by paired serum and plasma samples demonstrated high reproducibility, substantial concordance, and potential interchangeability for use in the VFA Peptide Microarray. CONCLUSIONS

[00136] The present study was proposed with the aim of optimizing the original VFA Peptide Microarray, composed of 726 peptides, to evaluate the 17DD yellow fever serological status, and this objective was successfully achieved. The optimized VFA Peptide Microarrays constitute a promising approach for serological evaluation of 17DD yellow fever vaccination status and segregation of NV and PV individuals. It was possible to successfully obtain a selection of peptides to be used in the evaluation of yellow fever vaccination serological status. The present invention allowed the development of a simple, timely test, with the possibility of using serum or plasma samples, which can be employed in routine clinical laboratories and in point-of-care rapid tests.

[00137] References AKONDY, Rama S.; et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. Journal of immunology, v.183, n. 12, p. 7919-7930, 2009. BRAZIL. Ministry of Health (MS). Secretariat of Health Surveillance. Yellow fever: a guide for health professionals. Federal District, 2017a. Petition 870260057968, dated 06 / 15 / 2026, pages 70 / 78 65 / 69 BRAZIL. Ministry of Health (MS). Secretariat of Health Surveillance. Health Surveillance Guide. Federal District, 2017b. BRAZIL. Ministry of Health (MS). Secretariat of Health Surveillance. Epidemiological Bulletin. Yellow Fever Monitoring, Brazil 2019, no. 18, 2019. CAMACHO, Luiz. Antonio Bastos, et al. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. Public health magazine, v. 38, η. 5, p. 671-678, 2004. CAMPI-AZEVEDO, Ana Carolina, et al. 17DD and 17D-213 / 77 yellow fever substrains trigger a balanced cytokine profile in primary vaccinated children. PloS one, v. 7, n. 12, e49828, 2012. CAMPI-AZEVEDO, Ana Carolina et al. Booster dose after 10 years is recommended following 17DD-YF primary vaccination. Hum Vaccines Immunother, v. 12, n. 2, p. 491-502, 2016. CAMPI-AZEVEDO, Ana Carolina et al. Heparin removal by ecteolacellulose pre-treatment enables the use of plasma samples for accurate measurement of anti-Yellow fever virus neutralizing antibodies. Journal of Immunological Methods Vol. 448, p. 9-20, 2017. COSTA-PEREIRA, Christiane et al. Multi-parameter approach to evaluate the timing of memory status after 17DDYF primary vaccination. PLoS Neglec Trop Dis, v. 12, n. 6, e0006462, 2018. COSTA-ROCHA, Ismael Artur et al. Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DDYellow Fever Vaccine. Front Immunol; v. 10, n. 1211, p. 1-11, 2019. Erratum in: Front Immunol, v. 10, n. 2433, p. 1-3, 2019. Petição 870260057968, de 15 / 06 / 2026, pág. 71 / 78 66 / 69 DAVIS, Emily H.; BARRETT, Alan DT. Structure-Function of the Yellow Fever Virus Envelope Protein: Analysis of Antibody Epitopes. Viral Immunology, v. 33, n. 1, p. 12-21, 2020. DOMINGO, Cristina et al. Yellow fever in the diagnostics laboratory. Emerging Microbes & Infections, v. 7, η. 1, p. 1-15, 2018. DOUAM, Florian; PLOSS, Alexander. Yellow fever virus: knowledge gaps impeding the fight against an old foe. Trends in Microbiology, v. 26, n. 11, p. 913-928,2018. EL-MANZALAWY, Yasser; DOBBS, Drena; HONAVAR, Vasant. Predicting flexible length linear B-cell epitopes. In: Computational Systems Bioinformatics: (Volume 7), p. 121-132, 2008a. EL-MANZALAWY, Yasser; DOBBS, Drena; HONAVAR, Vasant. Predicting linear B-cell epitopes using string kernels. Journal of Molecular Recognition: An Interdisciplinary Journal, v. 21, n. 4, p. 243-255, 2008b. FERREIRA, Clarissa de Castro et al. The 17D-204 and 17DD yellow fever vaccines: an overview of major similarities and subtle differences. Expert Review of Vaccines, v. 17, n. 1, p. 79-90, 2018. GOTUZZO, Eduardo et al. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg, v. 89, n. 3, p. 434-444, 2013. GOULD, Ernest et al. Emerging arboviruses: why today? One Health, v. 4, p. 1-13,2017. HOU, Jue, et al. A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine. Journal of immunology, v. 199, n. 4, p. 1476-1489, 2017. Petição 870260057968, de 15 / 06 / 2026, pág. 72 / 78 67 / 69 JOHANSSON, Michael A, et al. The whole iceberg: estimating the incidence of yellow fever virus infection from the number of severe cases. Transactions of The Royal Society of Tropical Medicine and Hygiene. v.108, n. 8; p. 482-487, 2014. JONKER, Emile FF; VISSER, Leonardus G.; ROUKENS, Anna H. Advances and controversies in yellow fever vaccination. Therapeutic Advances in Vaccines, v. 1, n. 4, p. 144-152, 2013. KLITTING, Raphaêlle et al. Molecular determinants of Yellow Fever Virus pathogenicity in Syrian Golden Hamsters: one mutation away from virulence. Emerging Microbes & Infections, v. 7, η. 1, p. 1-18, 2018. LARSEN, Jens Erik Pontoppidan; LUND, Ole; NIELSEN, Morten. Improved method for predicting linear B-cell epitopes. Immunome Research, v. 2, η. 1, p. 2, 2006. MARTINS, Reinaldo M. et al. 17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study. Human vaccines & Immunotherapeutics 9.4 p. 879-888, 2013. MCELROY, Kate L. et al. Role of the yellow fever virus structural protein genes in viral dissemination from the Aedes aegypti mosquito midgut. Journal of General Virology, v. 87, n. 10, p. 2993-3001, 2006. ORTIZ-MARTINEZ, Yeimer; PATINO-BARBOSA, Andrés Mauricio; RODRIGUEZ-MORALES, Alfonso J. Yellow fever in the Americas: the growing concern about new epidemics. FlOOOResearch, v. 6, 2017. PATKAR, Chinmay G.; KUHN, Richard J. Yellow fever virus NS3 plays an essential role in virus assembly independent of its known enzymatic functions. Journal of Virology, v. 82, n. 7, p. 3342-3352, 2008. Petição 870260057968, de 15 / 06 / 2026, pág. 73 / 78 68 / 69 PEPperPRINT®. Quick Start Guide, 2020. https: / / www.pepperprint.com / technology / downloads-and-protocols PepSlide® Analyzer. PepSlide® Analyzer 2.0 User’s Guide 2015. https: / / www.sicasys.de / pepslide / manuals / POSSAS, Cristina et al. Yellow fever outbreak in Brazil: the puzzle of rapid viral spread and challenges for immunisation. Memórias do Instituto Oswaldo Cruz 113, 2018. QUARESMA, Juarez A.S. et al. Immunity and immune response, pathology and pathologic changes: progress and challenges in the immunopathology of yellow fever. Reviews in Medical Virology, v. 23, n. 5, p. 305-318, 2013. REINHARDT, Barbara, et al. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. Journal of medical virology, v. 56, n. 2, p. 159-167, 1998. REZENDE, Izabela Mauricio de et al. Late-relapsing hepatitis after yellow fever. Viruses, v. 12, n. 2, p. 222, 2020. SIMÕES, Marisol et al. Evaluation of accuracy and reliability of the plaque reduction neutralization test (micro-PRNT) in detection of yellow fever virus antibodies. Biologicals, v. 40, n. 6, 399-404, 2012. VALIM, Valéria et al. Planned yellow fever primary vaccination is safe and immunogenic in patients with autoimmune diseases: a prospective noninterventional study. Frontiers in Immunology 11 p. 1382. 2020. VASCONCELOS, Pedro FC. Yellow fever: reflections on the disease, perspectives for the 21st century and the risk of reurbanization. Brazilian Epidemiological Journal, v. 5, n. 2, p. 244-258, 2002. Petition 870260057968, dated 06 / 15 / 2026, pp. 74 / 78 69 / 69 VASCONCELOS, Pedro Fernando da Costa. Yellow fever. Revista da Sociedade Brasileira de Medicina Tropical, v. 36, p. 275-293, 2003. WAGGONER, Jesse J.; ROJAS, Alejandra; PINSKY, Benjamin A. Yellow fever virus: Diagnostics for a persistent arboviral threat. Journal of Clinical Microbiology, vol. 56, no. 10, p. e00827-18, 2018. WIETEN, Rosanne W. et al. A single 17D yellow fever vaccination provides lifelong immunity; characterization of yellow-fever-specific neutralizing antibody and T-cell responses after vaccination. PloS One, v. 11, n. 3, e0149871, 2016. WORLD HEALTH ORGANIZATION et al. A global strategy to eliminate yellow fever epidemics (EYE) 2017-2026. 2018. Petição 870260057968, de 15 / 06 / 2026, pág. 75 / 78

Claims

1 / 3 CLAIMS 1. Process for the development of a peptide microarray immunoassay for serological assessment of yellow fever vaccination status, characterized by consisting of the following steps: (a) Selection of epitopes based on literature and prediction of linear B-cell epitopes using at least one of three different predictors; (b) Selection of epitopes from step (a) with the highest antigenic potential using secondary antibodies labeled with fluorescent molecules to select peptides reactive to sera from unvaccinated (NV) and primary (PV) vaccine samples; (c) Analysis using a computer program;(d) Identification of the most accurate fluorescence intensity (FI) thresholds and evaluation of their performance using the specific target peptides identified at each fluorescence intensity threshold, as well as performance indices expressed as a percentage for the correct classification of individual NV and PV samples; (e) Grouping of selective peptides from PV samples into matrices of different FI thresholds and identification of valid FI threshold zones with constant performance indices; (f) Combination of the sets of peptides capable of correctly classifying PV samples from Biorepository #1, from a controlled study, and Biorepository #2, from a real-world study, without redundancy (#239 + #144 - #45 redundant peptides = #338 peptides); (g) Selection of the highest FI thresholds and exclusion of peptides reactive with NV samples from both biorepositories.

2. Process according to claim 1, characterized in that the predictors of step (a) must be linear B-cell epitope predictors.

3. Process according to claim 1 or 2, characterized in that the program of step (c) must be a fluorescence intensity analysis program. Petition 870250035211, dated 02 / 05 / 2025, page 71 / 89 2 / 3 4. Process according to any one of claims 1 to 3, characterized in that the peptide microarray comprises sequences from SEQ ID NO: 1 to 136.

5. Peptide microarray plate for serological evaluation of yellow fever vaccination status, characterized in that it comprises at least two of the peptide sequences represented among SEQ ID NO: 1 to 136.

6. Peptide microarray plate according to claim 5, characterized in that it is preferably an optical microscope slide.

7. Peptide microarray plate according to claim 5 or 6, characterized in that the addition of the peptides to the microarray plate is preferably carried out by laser printing with solid-phase peptide synthesis.

8. Immunoassay for serological evaluation of vaccination status for Yellow Fever, characterized by comprising the following steps: a) Washing and blocking the peptide microarray plate defined in any one of claims 5 to 7; b) Pre-labeling the peptide microarray plate of step (a) with anti-IgG secondary antibody; c) Quantifying the fluorescence intensity signal; d) Washing the peptide microarray plate of step (c) and incubating with the test samples; e) Washing the peptide microarray plate of step (d) and incubating with anti-IgG secondary antibody; f) Washing the peptide microarray plate of step (e) and incubating with anti-HA control antibody; g) Washing the peptide microarray plate of step (f); h) Quantifying the fluorescence intensity signal. Petition 870250035211, dated 02 / 05 / 2025, page 72 / 89 3 / 3 9. Immunoassay, according to claim 8, characterized in that the test sample is preferably serum or plasma.

10. Immunoassay, according to claim 8 or 9, characterized in that the secondary antibody emits fluorescence in the red light spectrum, preferably at 650nm, and the control antibody emits fluorescence in the green light spectrum, preferably at 550nm.

11. Use of the peptide microarray plate as defined in any one of claims 5 to 7, characterized by being employed to differentiate PV from NV individuals for Yellow Fever.

12. Use according to claim 11, characterized in that the microarray comprises at least two of the sequences, preferably from SEQ ID No. 1 to SEQ ID No.

49.

13. Kit for serological evaluation of yellow fever vaccination status, characterized by comprising at least: (a) a peptide microarray plate as defined in any one of claims 5 to 7; (b) anti-IgG secondary antibody conjugated with fluorescent molecules; and (c) anti-HA control antibody conjugated with fluorescent molecules. Petition 870250035211, dated 02 / 05 / 2025, pp. 73 / 89